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1 INTRODUCTION 
1.1 Interleukin 6 
Interleukin 6 (IL-6) is the best characterized member of the IL-6 cytokine family. IL-6 was cloned in 1986 
and is described as a four α-helix bundle protein with a mass of 21-28 kDa dependent on its glycosylation 
(1, 2). A common structural feature for all IL-6-type cytokines are four long α-helices (A, B, C, D), which 
are arranged in an up-up-down-down topology (Fig. 1.1) (3). The majority of the IL-6 family members 
binds directly to heterodimers of gp130 with LIF-R, OSM-R, WSX-1 or GPL (Tab. 1.1). IL-6 requires the 
IL-6 receptor (IL-6R), which exists as a membrane (mIL-6R) and as solube form (sIL-6R) (4). Initally IL-6 
binds to its alpha-subunit IL-6R and the IL-6/IL-6R complex binds subsequently to homodimers of the 
common signal transducing beta-subunit gp130, initiating signal transduction (5). 
 
Figure 1.1: Structure of Interleukin 6. (A) Schematic representation of a four helix bundle cytokine 
with up-up-down-down topology. The four helices are designated A, B, C and D. (B) Ribbon 
representation of the four long α-helices of IL-6 solved by X-ray crystallography and NMR 
spectroscopy (6, 7). Helix A is highlited in red, B in green, C in yellow, D in blue. Picture was taken 
from Heinrich et al. (3). 
Viral IL-6 (vIL-6) is an orthologue to human IL-6, sharing about 25% identity of amino acid sequence and 
is expressed by the human herpesvirus (HHV) type 8, which is associated with Kaposi's sarcoma and 
Castlemans disease (8). vIL-6 can directly bind to gp130 homodimers without the requirement of an 
alpha-receptor (9). Therefore, vIL-6 is able to stimulate every cell and mimicking the effect of IL-6 and 
the soluble IL-6 receptor (sIL-6R). However, the affinity of vIL-6 to gp130 is 1000-fold lower compared 
to IL-6/sIL-6R. Viral IL-6 was used to characterize the binding sites of the three membrane distal 
domains (D1-D3) of gp130 in structural analysis (5, 10).  
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Table 1-1.1: Members of the IL-6 cytokine family. 
cytokine  alpha-receptor beta-receptors 
Interleukin 6 IL-6 (s)IL-6R gp130/gp130 
Viral IL-6 vIL-6  gp130/gp130 
Interleukin 11 IL-11 (s)IL-11R gp130/gp130 
Ciliary neutrotrophic factor CNTF (s)CNTF-R gp130/LIF-R 
Leukemia inhibitory factor LIF  gp130/LIF-R 
Cardiotropin-1 CT-1  gp130/LIF-R 
Neuropoietin NP (s)CNTF-R gp130/LIF-R 
Novel neurotrophin-1/ 
B cell stimulating factor 3 
NNT-1/ 
BSF-3 
(s)CNTF-R gp130/LIF-R 
Cardiotropin-like cytokine 
(+ Cytokine like factor) 
CLC 
(+ CLF-1) 
(s)CNTF-R gp130/LIF-R 
Oncostatin M OSM  gp130/OSM-R or gp130/LIF-R 
Interleukin 27 IL-27   gp130/WSX-1 
Interleukin 31 IL-31  GPL/OSM-R 
1.2 IL-6 signaling 
Gp130 has been described as preformed dimer. Hence its activation is induced by cytokine binding 
(Fig. 1.2 A) (11, 12). Previous studies suggested that two molecules of each, IL-6, IL-6R and gp130 are 
forming a hexameric signaling complex (Fig. 1.2 C) (5, 13, 14). Additionally, the assembly of a tetrameric 
complex consisting of one molecule of IL-6, one molecule IL-6R and two molecules gp130, is discussed 
(Fig. 1.2 B) (15). Pflanz et al. demonstrated that heterodimers of gp130 mutants lacking either one of two 
cytokine binding sites are active (16). This leads to the suggestion, that a tetrameric complex is sufficient 
to induce signaling as shown for CNTF (17). It is under debate that the hexameric complex is built by an 
excess of IL-6 and represents an inactive assembly (15). 
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Figure 1.2: Schematic representation of gp130 dimers (top view). The cytokine binding domains 
of gp130 include domain D1 (Ig) as well as the domains D2 and D3 (CBD). (A) Preformed inactive 
dimers of gp130. (B) Tetrameric assembly of IL-6/sIL-6R/(gp130)2. (C) Hexameric assembly of 
(IL-6/sIL-6R/gp130)2.The binding sites of IL-6 are subdivided in site I (contacting the IL-6R), site II 
(contacting the CBD of gp130) and site III (contact ing the Ig of gp130). 
Assembly of the IL-6/IL-6R/gp130 receptor complex leads to the activation of the intracellular associated 
Janus kinases (JAK1, JAK2), which become auto-phosphorylated. Subsequently distinct tyrosine residues 
of gp130 are phosphorylated (Y683, Y759, Y767, Y814, Y905 and Y915) and represent binding sites for proteins 
containing phospho-tyrosine binding motifs, such as Src-homology (SH) 2 domains. The Signal 
Transducer and Activator of Transcription 3 (STAT3), as the prominent transcription factor in IL-6 
dependent signaling, binds to phospho-YXXQ motifs in gp130 (Y767RHQ, Y814FKQ, Y905LPQ and 
Y915MPQ) and is trans-phosphorylated by JAK1/JAK2 at Y705, which leads to its homodimerization and 
translocation into the nucleus. In addition, phosphorylation of Y759 of gp130 generates a binding site for 
the protein tyrosine phosphatase SHP2, which becomes phosphorylated by JAK1/JAK2 as well and 
recruits the adaptor protein Grb2, thereby initiating the mitogen-activated protein kinase (MAPK) 
pathway (Fig. 1.3). 
  
Figure 1.3: IL-6 induces the JAK/STAT pathway and the MAPK cascade.  JAK1/2 mediated 
phosphorylation of distinct tyrosine residues of gp130 initiates either STAT3 or SHP2 mediated 
signaling. Picture was adapted from Heinrich et al. (18). 
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One hallmark of IL-6 is its ability to activate cells in two different ways, due to the differential expression 
of the alpha-subunit IL-6R, which is exclusively expressed on hepatocytes and distinct leukocyte 
populations. Therefore, only a small subset of cell populations can be activated via the binding of IL-6 to 
the membrane bound IL-6R, thereby initiating the activation of gp130, which is described as ‘classic 
signaling’ of IL-6 (Fig. 1.4). However, a soluble form of the IL-6R (sIL-6R) can be generated by 
alternative splicing or proteolytic cleavage (shedding) via A Disintegrin And Metalloprotease (ADAM) 
(19, 20). This soluble receptor binds free IL-6 molecules to form complexes, which subsequently bind the 
membrane associated beta-receptor subunit gp130 (Fig. 1.4). This process has been designated 
‘trans-signaling’ and has the potential to activate a wide spectrum of cells. Obviously, IL-6 classic signaling 
represents more specificity as IL-6 trans-signaling. The significance of the different ways of signaling in 
the context of inflammation, regeneration or tumor development is part of ongoing investigations 
(21, 22).  
 
Figure 1.4: Classic signaling and trans-signaling of IL-6. In the classic signaling gp130 is 
activated by a complex of IL-6 and the membrane bound IL-6R. The trans-signaling is elicited by IL-6 
in a complex with soluble IL-6R, which is cleaved from the membrane by ADAM 17. Thereby, the 
activation of gp130 can occur in (1) an autocrine or (2) a paracrine manner. Picture was taken from 
Scheller et al. (23). 
To investigate the role of trans-signaling, a fusion protein consisting of IL-6 and the sIL-6R was generated 
in our laboratory. This molecule, named Hyper-IL-6 (HIL-6), is a potent stimulator of all gp130 
expressing cells and reveals its full activity at 100 to 1000-fold lower concentrations than unlinked IL-6 
and sIL-6R (24, 25). Peters et al. showed that Hyper-IL-6 binds with high affinity to gp130 and is less 
efficiently internalized (26).  
1.3 The pathophysiological role of IL-6 signaling 
IL-6 is secreted by cells of the immune system, e.g. lymphocytes, monocytes and macrophages and other 
mesenchymal cells like adipocytes, endothelial cells, fibroblasts, keratinocytes, myocytes and osteoblasts, 
thereby acting in an autocrine, paracrine and endocrine manner (27). Under physiological conditions the 
serum level of IL-6 is low, whereas tissue damage or pathological stimuli result in a significant increase 
(28). 
IL-6 has been identified as an important factor for the immune system. Initially IL-6 has been described to 
be crucial for the terminal differentiation of B cells into antibody secreting cells (29, 30). In addition, it has 
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been shown that IL-6 promotes the generation of CD8+ cytotoxic T cells from mature as well as 
immature human T cells (31). Furthermore, IL-6 orchestrates the transition from innate to acquired 
immunity by the attraction of distinct immune cells to the site of inflammation. Endothelial cells activated 
by microbes produce various cytokines including IL-6 acting in an autocrine manner. IL-6 signaling is 
linked to the induction of chemokine expression in endothelial cells leading to the attraction of 
neutrophiles to the site of infection, which are then replaced by monocytes and T cells in the cause of 
infection. Differentiation of monocytes into macrophages, the resolution of neutrophiles and the 
attraction of T cells to the site of infection are essentially triggered by IL-6 signaling (32, 33). Another 
crucial role of IL-6 has been shown in the context of autoimmune diseases, where IL-6 in combination 
with TGF-β induce the development of Th17 cells (34). An overproduction of IL-6 is often associated 
with pathological conditions caused by Th17 cells, such as multiple sclerosis (MS) and rheumatoid arthritis 
(RA) (35, 36). Additionally, high levels of IL-6 and sIL-6R in the serum of patients often correlate with the 
severity of disease, seen in arteriosclerosis and liver diseases. Moreover, it has been shown that IL-6 
knock-out mice (IL-6-/-) were not capable to clear bacterial infections from L. monocytogenes (37, 38). In 
addition, Okuda et al. showed that IL-6-/- mice are protected against autoimmune diseases, such as 
experimental autoimmune encephalomyelitis (EAE), reflecting the bivalent role of IL-6 (39). 
The liver represents a privileged site for IL-6 stimuli due to the expression of the membrane bound IL-6R 
on hepatocytes and their susceptibility to IL-6 classic signaling. Activation of the IL-6 dependent pathways 
in hepatocytes initiates the acute phase response and leads to the upregulation of acute phase genes, such 
as serum amyloid A (SAA), haptoglobin, C-reactive protein (CRP), fibrinogen, and complement factors 
(40, 41). These factors are important for opsonization and killing of microbes, as well as for attraction of 
immune cells (chemotaxis). Unchallenged IL-6-/- mice showed no obvious phenotype, besides a massively 
suppressed acute phase response following infection with a vaccine virus or with the bacterium 
L. monocytogenes (42). Furthermore IL-6 is involved in regenerative processes and the central role of IL-6 
signaling for liver regeneration is well known (43). Liver failure and defective hepatocyte regeneration was 
observed in IL-6-/- mice (44). The importance of IL-6 for liver regeneration following tissue damage due 
to toxins, alcohol abuse or viral infection (HCV) is well described (22, 45, 46). This correlates with the 
necessity of STAT3 for the induction of the acute phase response during inflammation and liver 
regeneration (44, 47, 48). Moreover, it has been shown that liver regeneration was improved by a 
Hyper-IL-6 therapy following partial hepatectomy or D-Galactosamine caused liver injury (45, 49). 
Additional an adenoviral vector encoding for Hyper-IL-6 was used for gene therapy to reverses fulminat 
hepatic failure in mice (50). The positive effect of IL-6 on liver regeneration is linked to its impact on 
hepatocyte proliferation. 
However, persistent overexpression of IL-6 seems to be associated with cancer. It has been shown that 
formation of adenomas and hyperplasia of the liver is connected to an overexpression of IL-6 and sIL-6R 
in mice (51, 52). This stands in line with previous clinical studies, which reported elevated levels of 
circulating IL-6 in patients with chronic hepatitis, alcoholic liver diseases, and liver cirrhosis (53–56). In 
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addition, elevated IL-6 serum levels were found in patients with hepatocellular carcinoma (HCC), which 
has been shown to correlate with the tumor mass, cancer invasiveness and with the impairment of liver 
function as well as with the degree of liver fibrosis (57–60). Furthermore, IL-6 has been implicated in 
many diseases, e.g. diabetes, obesity, arteriosclerosis, rheumatoid arthritis, psoriasis and is connected to 
different types of cancer (61–66). Elevated serum levels of IL-6 has been shown to correlate with the stage 
of colorectal cancer and distinct tumors, such as esophageal cancer, renal cell carcinoma, multiple 
myeloma, prostate and ovarian cancer have the characteristic of elevated IL-6 secretion (67). In this 
context, IL-6 has been identified as a growth factor for renal carcinoma and multiple myeloma cells 
(68, 69).  
1.4 STAT3 as an oncogenic factor 
IL-6 mediated activation of STAT3 induces the expression of a variety of genes, which are important for 
cell cycle, apoptosis, signaling, angiogenesis, inflammation, wound healing and invasion, e.g. c-myc and 
pim-1 (18, 70, 71). It is known that inflammation triggers tumor initiation and enhances tumor 
progression as well as metastasis (72, 73). In distinct tumor types exaggerated STAT3 activation is 
described and displays a major oncogenic factor (74–76). The persistent phosphorylation of STAT3 can 
be seen in human epithelial cancer cell lines as well as in primary tumors including hepatocellular 
carcinoma, breast, prostate, colon, head and neck cancers and in several hematological malignancies 
(77-81). In addition STAT3 activation is important for the development of epithelial cell tumors (82–84). 
Known before that STAT3 is a key player in liver inflammation and cancer, it has been recently shown by 
Pilati et al. that about 12% of inflammatory hepatocellular adenomas (IHCAs) carry STAT3 mutations, 
which seems to be associated with benign proliferation of hepatocytes in human (85, 86). Moreover, a 
constitutive active variant of STAT3 (STAT3C) was described leading to an increased VEGF expression 
and tumor angiogenesis in mice (72, 87, 88).  
Recently a tumor suppressor role of STAT3 has been found in glioblastoma, which is a highly malignant 
brain tumor. De la Iglesia et al. reported that STAT3 plays a pro-oncogenic or tumor suppressive role 
depending on the mutational profile of the tumor (89). Furthermore, Ecker et al. demonstrated that a 
constitutive active version of Stat3alpha (Stat3alphaC) suppressed the c-myc dependent transformation of 
mEF cells, which were deficient for p53 (90).  
1.5 SOCS3 as a competent inhibitor of IL-6 signaling 
The members of the Suppressor Of Cytokine Signaling (SOCS) family are inhibitors of Janus kinases and 
their expression is upregulated by e.g. IL-6, LIF, IL-11 and OSM (18, 91). SOCS3 specifically affects the 
signaling mediated by IL-6 and gp130 (92). SOCS proteins contain a central SH2 domain, as well as a 
C-terminal domain (SOCS box). The SH2 domain of SOCS3 has a slightly higher affinity to the 
phosphorylated tyrosine Y759 at the intracellular domain of gp130 than SHP2. Thereby the activation of 
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the MAPK cascade is abrogated. Furthermore, it has been shown that the activity of JAK2 is inhibited by 
SOCS3 (93). Other studies suggest that SOCS proteins are interacting with elongin B and C and might be 
part of E3 ubiquitin ligases, which are involved in the degradation of their binding partners (94, 95).  
SOCS3 deficient mice die at mid-gestation owing to placental insufficiency, which is linked to aberrant 
signaling through the LIF-R (96, 97). Furthermore, it has been shown that a conditional deletion of 
SOCS3 in hepatocytes promotes fibrosis and hepatitis-induced hepatocarcinogenesis (98, 99). Mice 
expressing a gp130 knock-in mutation (gp130Y757F) are deficient in SHP-2 and SOCS3 binding and were 
examined by Tebbutt et al. (100). This hyperactivation of STAT3 leads to an age-dependent enlargement 
of the stomach, the proximal small intestine and the spleen as well as to the development of gastric 
adenomas. Jenkins et al. showed that the formation of gastric adenomas and the reduced survival of 
gp130Y757F/Y757F mice could be partially rescued in gp130Y757F/Y757F STAT3+/− mice (101). However, 
compared to STAT3 deficient mice, gp130Y757F mice were protected in a model of severe colitis (74, 101). 
1.6 Glycoprotein 130 
The members of the IL-6 family, besides IL-31, signal through the ubiquitously expressed type I cytokine 
receptor glycoprotein 130 (gp130, CD130) (Tab. 1.1). It is known that a complete deletion of gp130 is 
lethal to mice (102). Therefore, conditional gp130 knock-out mice (gp130flox) were used to study the 
physiological function of gp130 in vivo. For instance, the lack of hepatic gp130 promotes liver injury, 
which was confirmed in a variety of studies (46, 103–105). Moreover, mice expressing a hyperactive 
variant of gp130, due to the lack of suppression via SOCS3 (gp130Y757F), showed improved survival in a 
model of DSS colitis (100). 
Structurally, the extracellular domain of gp130 is composed of one immunoglobulin-like domain (Ig, D1), 
a cytokine binding domain consisting of the domains D2 and D3 (CBD), three fibronectin domains 
(FNIII, D4 - D6) followed by the transmembrane (TM) and the intracellular domain (ICD), which is 
associated with a Janus kinase (JAK) (Fig. 1.5 A). Domain D1 of gp130 is involved in the binding of IL-6, 
such as the domains D2 and D3 (CBD). The FNIII domains D4 to D6 seem to be essential for the 
transmission of the signal to the cytoplasmatic portion (106–109). The basic structure of the CBD is a 
β-sandwich, consisting of a three-stranded (A, B, E) and a four-stranded (C, C’, F, G) β-sheet. The 
domains are connected via a short helix (Fig. 1.5 B, C).  
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Figure 1.5: Structure of gp130 and the cytokine binding domain.  (A) Schematic representation of 
gp130. Domain D1 represents the Ig-like domain, the domains D2 and D3 form the cytokine binding 
domain (CBD) and the domains D4 to D6 are fibronectinIII domains, which are followed by the 
transmembrane domain (TM) and an intracellular domain (ICD), associated to Januns kinase (JAK). 
(B) Ribbon representation of the crystal structure of the CBD. Helical segments are shown i n red and 
β-strands in green. (C) Topology diagram of the CBD of gp130 (helices are represented by cylinders 
and β-strands by arrows). Pictures B was taken from Bravo et al. (106). 
Three different binding sites are described for the human IL-6/sIL-6R/gp130 complex, which are based 
on the structure of vIL-6 bound to gp130 (5, 10, 110). Binding site I is generated between humen (h)IL-6 
and the domains D2 and D3 of the sIL-6R, whereas site II describes the interaction of the IL-6/sIL-6R 
complex with the domains D2 and D3 of gp130 and site III the interaction with domain D1 of another 
gp130 molecule (Fig. 1.6). Site II consist of site IIa, which occurs only between the bound IL-6 and the 
domain D2 of gp130 and site IIb, which is between the bound sIL-6R and domain D3 of gp130 (Fig. 1.6). 
This assembly interacts with a second gp130 molecule forming the binding sites IIIa and IIIb. Both parts 
of site III are connected to domain D1 of gp130, which has been shown to be important for gp130 
activation (16, 111). Furthermore, the structure of the site III interface reveals that the N-terminal tail of 
domain D1 can insert into a groove on the surface of IL-6 (112). Although the crystal structure of the 
gp130 domains D1 to D3 in complex with viral IL-6 is solved, it is not clear how the binding of the 
IL-6/sIL-6R complex leads to the activation of gp130 in detail (106, 113, 114). Thus, the binding of the 
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IL-6/sIL-6R complex to gp130 is a prerequisite for its activation and induction of the signaling via 
STAT3. 
 
Figure 1.6: The signaling complex of human IL-6, hIL-6R and gp130. Representation of the ribbon 
structure of two molecules human IL-6 in complex with two molecules of human IL-6 receptor and two 
molecules gp130. Site I engages domain D2 and D3 of the human IL-6R (hIL-6R), site II the CBD (D2 
and D3) of the first gp130 molecule and site III the Ig-like domain (D1) of a second gp130 molecule. 
Pictures were taken from Boulanger et al. (5). 
It has been assumed since a long time that activation of the gp130 mediated signaling is triggered by its 
dimerization. However, preformed inactive homodimers were identified for gp130, as described for 
IL-17R, TNF-R1 and IFN-γR (115–118). Thereby, the formation of gp130 homodimers was found to be 
independent of the JAK activity. Blocking of gp130 dimerization and subsequent JAK activity was 
achieved by using the monoclonal anti-gp130 antibody B-R3, which binds to an epitope at domain D2 of 
gp130 (119, 120). Ligand independent homodimerization of gp130 and heterodimerization of gp130 and 
LIF-R was reported by Giese et al. using Bimolecular Fluorescence Complementation (BiFC), which 
detects predominantly stable protein-protein interactions (11). The used gp130 constructs were C-terminal 
tagged with the corresponding halves of YFP, therefore not signaling competent and did not reflect the 
natural gp130 activation. Tenhumberg et al. used Förster Resonance Energy Transfer (FRET) to detect 
dimerization of two fluorescently-tagged gp130 variants (12). Preformed but inactive dimers were found 
and the addition of the respective ligand led to enhanced dimer formation. Furthermore, this study 
revealed that gp130 could be co-precipitated with the LIF-R as well as with other gp130 variants in the 
absence of a ligand. 
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1.7 Natural occurring mutations of gp130 
Recently, in-frame deletions of gp130 were found in 60% of human inflammatory hepatocellular adenoma 
(IHCA), which exhibit ligand independent activation (121). These deletions differ in length, but cluster all 
around the EF loop of domain D2 of gp130, representing the IL-6 contact site (Fig. 1.7). Out of 
twenty-six identified gp130 mutations found in IHCAs, 16 mutations were unique, small in-frame 
deletions and one mutation was a 33 base pair in-frame duplication in exon 6 (Tab. 1-2). Out of these 17 
mutations, Rebouissou et al. analyzed two frequent deletions (delS187–Y190 and delY186–Y190) and two 
infrequent mutants (delV184–Y186, S187A and delK173-D177) in the hepatocellular Hep3B cell line. The 
expression of the gp130 deletion mutants was sufficient to activate STAT3 and the downstream acute 
phase inflammatory genes. Interestingly, SOCS3 expression, which normally suppresses IL-6 mediated 
STAT3 activation was induced as well, but had no effect on the constitutive STAT3 phosphorylation. 
Moreover, they showed in co-immunoprecipitation studies that the gp130 deletion mutant delS187–Y190 
can form homodimers as well as heterodimers with wildtype gp130, in a IL-6 independent manner. 
Interestingly, the activity of the gp130 deletion mutant delS187–Y190 is driven by its homodimerization, 
as overexpression of wildtype gp130 impaired gp130 delS187–Y190 activity in a dose-dependent manner. 
Found frequently in IHCAs, only 1.8% of hepatocellular carcinoma (HCC) showed a correlation to these 
gp130 mutations. The most frequently activated oncogene in HCC is β-catenin, which was found in 
IHCAs as well (122). Furthermore, Pilati et al. showed that 12% of IHCAs lacking mutations for gp130 
harbor somatic activating mutations for STAT3 (85).  
 
 
Figure 1.7: In-frame deletions of gp130 found in IHCAs. Overview of gp130 somatic mutations 
identified in inflammatory hepatocellular adenomas (IHCAs). Picture was taken from Rebouissou et 
al. (121). 
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Table 1-2: List of the deletions located in domain D2 of gp130. 
Number of  tumors Amio acid change Mutation 
6  S187-Y190  Deletion  
4  Y186-Y190  Deletion  
3  V189-V192  Deletion  
2  T188-F191, V192I  Deletion, point mutation  
1  K168-N192 Deletion  
1  K183-D177  Deletion  
1  V184-Y186, S187A  Deletion, point mutation  
1  Y186-F191, V192F  Deletion, point mutation  
1  S187-F191  Deletion  
1  T188-F191, V192T  Deletion, point mutation  
1  Y190-V192, N193S  Deletion, point mutation  
1  F191L, V192-I194  Deletion, point mutation  
1  V192-I194  Deletion  
1  N193, I194F  Deletion, point mutation  
1  E195-V196  Deletion  
1  K206-P216, G205R  Duplication, point mutation 
1  D215  Deletion  
 
1.8 A constitutive active variant of gp130 
To point out the consequences of ligand independent gp130 activity and STAT3 signaling, an artificial 
constitutive active variant of gp130 was generated in our laboratory. This construct is named 
Leucin-gp130 (L-gp130). Here, the extracellular domain of human gp130 was truncated 15 amino acids 
above the transmembrane domain and replaced by the leucine zipper motif of c-Jun. C-Jun is known to 
form heterodimers with c-Fos, which constitute the transcription factor AP-1. However, c-Jun is able to 
form homodimers as well. The strong interaction relies on the coiled-coil structure with a hydrophobic 
core built by leucine residues. Additionally, cysteine residues were introduced to stabilize the leucine 
zipper (LZ) by a disulfide bond. An N-terminal Flag-tag was added for the detection of protein 
expression. The intracellular part and the transmembrane domain were left unchanged, to achieve normal 
signaling properties (Fig. 1.8). Expression of L-gp130 in different cell lines (HepG2, Cos-7 and Ba/F3 
cells) showed IL-6 independent phosphorylation of STAT3 as well as a cytokine independent cell growth. 
These data indicate that L-gp130 is sufficient to activate a gp130-type signaling in an IL-6 independent 
manner. Moreover, in vitro differentiation of murine embryonic stem cells was completely suppressed in 
cells expressing L-gp130 (123). 
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Figure 1.8: Schematic representation of L-gp130 signaling. (A) Inactive preformed homodimers of 
wildtype (wt) gp130. (B) The signaling competent complex of IL-6/sIL-6R/(gp130)2 and (C) L-gp130, 
containing a leucine zipper (LZ) and a disulfide bond (S-S) instead of the wildtype extracellular 
domains. Picture was taken from Stuhlmann-Laeisz et al. (123). 
1.9 Inducible regulation of gene expression via the Tet-system 
The inducible regulation of gene expression in vitro and in vivo can be achieved by the Tet-system. The 
origin of this widely-used application is the antibiotic resistance of E. coli. This system was adjusted to be 
more specific in binding of eukaryotic DNA, so that it can be used in mammalian cells (124). The 
principle of inducible gene expression is the simultaneous application of two plasmids. One vector 
expressing the gene of interest under control of an inducible tetracycline responsive promoter element 
(TRE) is combined with a second vector, which expresses the tetracycline transactivator protein (tTA). 
tTA is a fusion protein, consistig of the Tet-repressor domain (TetR) from E. coli and the VP16 domain 
from the herpes simplex virus. The TetR unit is responsible for binding to the Tet operator (TetO), which is 
part of the promoter region. The VP16 domain is a strong activator of transcription. The reverse 
transactivator (rtTA) contains a modified TetR domain and exhibits altered binding properties to TRE 
(Fig. 1.9 A) (125). 
 
Figure 1.9: Schematic representation of: (A) The tetracycline transactivator proteins tTA and 
rtTA and of (B) The tetracycline promoter element (TRE). The TetR domain of rtTA is changed 
relating to its doxycycline affinity. 
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Selective expression of the transactivators (tTA/rtTA) can be achieved via a tissue specific promoter 
(Fig. 1.10). The expression of the gene of interest is controlled by the tetracycline responsive promoter 
element (TRE), which consists of seven repeats of TetO, separated by spacer sequences (Fig. 1.9 B). This 
sequence is flanked by two hCMV minimal promoters, which are responsible for an equal expression of 
two genes. Usually, a reporter gene (e.g. firefly luciferase) is used as second transgene. It has been shown, 
that these constructs can exhibit low basal expression in the absence of the activator. 
 
Figure 1.10: Inducible gene expression of L-gp130 and firefly luciferase  via the Tet-system. 
Using the Tet-off system, the transgene is expressed in the absence of Dox, whereas in the Tet -on 
system Dox is needed for transgene expression. Dox: doxycycline, tTA: tetracycline transactivator 
protein, rtTA: reverse tetracycline transactivator protein, TetR: Tet repressor, VP16: activating 
domain, TRE: tetracycline responsive promoter element.  
By means of tetracycline or its derivate doxycycline (Dox) the inducible gene expression can be switched. 
Thereby, initiation of gene expression is achieved in two different ways. Induction of gene expression in 
the absence doxycycline is designated as Tet-off. Thereby, the transactivator tTA binds to TRE and 
induces gene expression. Supplementation of doxycycline induces a conformational change of the tTA, 
which represses its binding to the promoter and results in inhibition of the gene expression. This system 
can be used vice versa (designated as Tet-on) by using the reverse transactivator (rtTA). Here, the binding 
properties of the tTA are changed to a doxycycline dependent binding to the promoter and therefore rtTA 
induces gene expression in the presence of doxycycline (Fig. 1.10). Recently, a second generation of rtTA 
(rtTA-M2) with higher sensitivity for doxycycline was found by mutagenesis. 
As Gossen and Bujard showed, 0.1 to 1 µg/ml of doxycycline is an adequate concentration to repress 
luciferase activity using the Tet-off system in vitro (124). For induction of gene transcription via the Tet-on 
system a 10-fold higher concentration is required. In vivo studies, using the Tet-on as well as the Tet-off 
system, revealed a doxycycline concentration of 0.2 to 2 mg/ml, which was given to mice via drinking 
water (126).  
Comparing both systems, the advantage of the Tet-off system is the requirement of low concentrations of 
doxycycline. The major disadvantage is the long term treatment of mice with doxycycline and the resulting 
incomplete clearance of doxycycline from the body, because initiation of gene expression is dependent on 
the fast clearance of doxycycline (K. Schönig, ZI Mannheim, personal communication). The advantage of 
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the Tet-on system is its fast induction capability but a 10-fold higher concentration of doxycycline is 
required compared to the Tet-off system (127).  
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1.10 Aim of this work 
Recently, activating mutations of gp130 and less frequently activating STAT3 mutations have been found 
in liver adenoma (85, 121). Although crystal structures of gp130 and gp130 complexes are available, the 
detailed mechanism of gp130 activation is unresolved. Furthermore, it is unclear if ligand independent 
activation of gp130 in hepatocytes is sufficient to drive liver tumor formation. 
1. We aimed to decipher the mechanism of ligand independent gp130 activation and to get an 
insight into the mechanism of gp130 activation in general. We therefore wanted to apply a 
rational driven mutagenesis approach based on available gp130 crystal structures. The aim was to 
identify amino acids that are critical for the autoinhibition of gp130 and therefore play a role in 
gp130 activation.  
2. Using an artificial, constitutive active gp130 variant (L-gp130) we aimed to analyze the 
physiological consequences of persistent gp130 activation in the liver using transgenic mice. The 
aim was to generate and establish double transgenic mice that would allow for a tetracycline 
inducible expression of L-gp130 in the liver. The consequences of persistent gp130 activation in 
hepatocytes should then be analyzed by biochemical and histological methods.  
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2 MATERIAL 
2.1 Chemicals 
Basic chemicals were purchased from Carl Roth, Sigma-Aldrich or Merck, unless otherwise stated. 
Chemicals of particular interest are listed below. 
AppliChem 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT ) 
 Leupeptin 
 Aprotinin 
 Pepstatin  
Fermentas/ DreamTaq™ polymerase 
Thermo Scientific Phusion® Hot Start II polymerase 
 Revert Aid™ reverse transcriptase 
 Proteinase K 
 Gene Ruler™ 1kb DNA ladder 
 dNTPs (dATP, dCTP, dGTP, dTTP) 
 CIAP alkaline phophatase 
 FastAP™ alkaline phophatase 
 T4 DNA Ligase 
 T4 Polynucleotide Kinase 
 Page Ruler™ Plus  
Pierce® Protein G Agarose 
Sigma-Aldrich Polybrene 
 Puromycine 
 Doxycycline hyclate 
 PMSF 
 Saponin  
 Sodium orthovanadat (Na3VO4 ) 
 
2.1.1 Enzymes 
All other enzymes used including restriction enzymes were purchased from Fermentas/ Thermo 
Scientific. 
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2.1.2 Recombinant cytokines 
Hyper-IL-6 fusion protein of the human IL-6 and the human sIL-6R; kindly provided by 
Dr. Inken Lorenzen and Prof. Dr. Achim Grötzinger (Department of 
Biochemistry, CAU Kiel) 
Murine IL-3 Peprotech (#213-13), Immunotools (#12340032) 
2.2 Solutions and buffers 
 
2.2.1 Microbiology 
LB medium 10 g NaCl 
 10 g Peptone/ Tryptone 
 5 g Yeast extract 
 Ad 1 l ddH2O 
 Autoclave 
LB Agar 20 g Agar-Agar 
 1 l LB medium 
 Antibiotic (Ampicillin 100 µg/ml) 
KCM buffer (5x) 500 mM KCl  
 150 mM CaCl2 
 250 mM MgCl2 
2.2.2 SDS-PAGE 
Running gel (10%) 3.87 ml ddH2O 
(10 ml) 2.55 ml 1.5 M Tris-HCl (pH 8.8) 
 100 µl 10% SDS 
 3.3 ml 30% Acrylamide 
 100 µl 10% APS 
 10 µl TEMED 
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Stacking gel (4%) 3.72 ml ddH2O 
(5 ml) 625 µl 0.5 M Tris-HCl (pH 6.8) 
 50 µl 10% SDS 
 670 µl 30% Acrylamide 
 50 µl 10% APS 
 10 µl TEMED 
SDS running buffer 25 mM Tris-HCl, pH 8.3 
 192 mM glycine 
 0.1% (w/v) SDS 
Laemmli buffer (5x)  185 mM Tris-HCl (pH 6.8)  
 50% glycerol  
 10% SDS  
 5% β-mercaptoethanol  
 0.05% bromphenol blue 
2.2.3 Western blot 
NETG was used as buffer for blocking, washing and antibody dilution. 
NETG 150 mM NaCl 
 5 mM EDTA 
 50 mM Tris-HCL, pH 7.5 
 0.02% (v/v) Tween-20 
 0.04% (w/v) gelatine 
 Let gelatine soak in ddH2O and boil before adding to the solution 
Transfer buffer  25 mM Tris-HCl 
(pH 8.3) 192 mM glycine 
 20% (v/v) methanol 
Stripping solution 15 g glycine 
(pH 2.2) 1 g SDS 
 10 ml Tween-20 
 Ad 1 l ddH2O 
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2.2.4 Lysis buffer 
Tissue lysis buffer 150 mM NaCl 
 50 mM Tris-HCl (pH 7.4) 
 2 mM EDTA 
 1% (w/v) Triton X-100 
 1% (w/v) NP-40 
 1 mM Na3VO4 
 1 mM NaF 
 1x tablet Complete (Roche)/ 50 ml lysis buffer (protease inhibitor cocktail) 
Co-IP buffer 50 mM HEPES 
(pH 7.4) 150 mM NaCl 
 1 mM EDTA 
 2 mM EGTA 
 0.5% (w/v) NP-40 
RIPA buffer 50 mM HEPES 
(pH 7.4) 150 mM NaCl 
 1 mM EDTA 
 1% (w/v) NP-40 
 0.5% (w/v) sodiumdeoxycholate 
 0.1% (w/v) SDS 
2.2.5 Inhibitors   
1 mM (f.c.) PMSF (in MetOH), serine protease inhibitor 
1 µg/ml (f.c.) Leupeptin, protease inhibitor 
2 µg/ml (f.c.) Aprotinin, trypsin inhibitor, serine protease inhibitor 
10 µg/ml (f.c.) Pepstatin, protease inhibitor 
1 mM (f.c.) Na3VO4 (Sodiumorthovanadat), protease inhibitor 
2.2.6 Cell culture media and solutions 
Cell culture media and solutions were purchased from PAA. Media was supplemented with 10% (v/v) 
heat-inactivated FCS. 
DMEM Dulbecco’s Modified Eagle Medium (high glucose 4.5 g/l and stable glutamin) 
RPMI 1640 Roswell Park Memorial Institute Medium 
IMDM Iscove’s modified DMEM (with L-Glutamine) 
FCS Fetal Calf Serum 
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Trypsin-EDTA 
Penicillin-Streptomycin 
2.2.7 Flow cytometry (intracellular staining) 
Staining buffer  PBS (Ca2+, Mg2+), pH 7.4 - 7.6 
 2% (v/v) FCS (heat-inactivated) 
 0.2% (v/v) sodium azide 
Fixation buffer PBS (Ca2+, Mg2+) 
 4% (v/v) formaldehyde 
Permeabilization buffer PBS (Ca2+, Mg2+), pH 7.4 - 7.6 
 2% (v/v) FCS (heat-inactivated) 
 0.2% (v/v) sodium azide 
 0.5% (v/v) Saponin  
Superperm buffer PBS (Ca2+, Mg2+), pH 7.4 - 7.6 
 2% (v/v) FCS (heat-inactivated) 
 0.2% (v/v) sodium azide 
 0.5% (v/v) Saponin  
 25% (v/v) FCS 
2.2.8 MTT cell viability assay 
MTT solution 5 mg/ml MTT in PBS 
Solubilization buffer 10 mM HCl 
 10% (w/v) SDS  
2.2.9 Southern blot 
20 x SSC 3 M NaCl 
(pH 7.0) 300 mM NaCitrat  
 adjust pH with HCl 
Depurination buffer 0.25 M HCl  
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Denaturation buffer 0.5 M NaOH 
 1.5 M NaCl 
Neutralisation buffer 1 M Tris-HCl 
(pH 8.0) 1.5 M NaCl 
Churchbuffer (1 l) 500 mM NaPI (NaH2PO4, Na2HPO4) 
 7% (w/v) SDS 
 1% (w/v) BSA 
 1 mM EDTA (pH 8.0) 
2.2.10 DNA buffer 
TBE (0.5x) 44.5 mM boric-acid 
 10 mM EDTA, pH 8.0 
 44.5 mM Tris-HCl 
DNA-loading buffer (5x) 20% (w/v) glycerol in TBE buffer 
 0.025% (w/v) bromphenol blue  
2.3 Isotopes 
Radioactive isotopes were used for radioactive labeling of nucleotides of DNA or RNA. The isotopes of 
phosphorus are the beta-emitter 33P and 32P. Thereby, 33P is the long-lasting radioactive isotope although it 
has lower energy beta emission compared to 32P. All isotopes were purchased from MP Biomedicals 
Europe. 
Tabelle 2-1: Radioactive isotopes for Southern blot analysis used in this study. 
Istotope Specific activity Energy Half-life 
alpha32P dATP (#33002x) 25 Ci/ mmol;  
925 GBq/mmol  
1.71 MeV 14.263 days 
alpha33P dATP (#58200) 3000 Ci/mmol; 
111 TBq/mmol  
0.25 MeV 25.34 days 
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2.4 Plasmids and Primers 
 
2.4.1 Plasmids 
The bidirectional expression vector pBI5 contains of a tetracycline responsive promoter element (TRE). 
This promoter is composed of a heptameric Tet-operator sequence, which is flanked by two divergently 
orientated hCMV minimal promoters (Fig. 1.9). The expression vectors pBI5-GFP and pTan-Pur 
containing the sequence for the Green Fluorescent Protein (GFP) and the tetracycline transactivator 
(tTA), respectively were kindly provided by Anders Strom from the Department of Biosciences and 
Nutrition (Karolinska Institute, Sweden). The vector pTan-Pur was modified from Shockett et al. (125). 
The Tet-expression vectors hCMV-tTA (pUHD15-1), Lap-tTA (pUHD 15-30), hCMV-rtTA 
(pUHD 17-1) and Lap-rtTA (pUHD 61-30) containing the sequence for tTA or reverse tTA (rtTA) were 
kindly provided by Dr. Kai Schönig (Zentralinstitut für seelische Gesundheit,  Mannheim) (Fig. 4.22). The 
mammalian expression vectors p409-gp130 wt and gp130 ΔYY were provided by Jan Sommer and Timo 
Effenberger (Departement of Biochemistry, CAU Kiel). All plasmids contain an ampicillin resistance gene. 
The mammalian expression vector pMOWs was used for retroviral transduction of eukaryotic cells. It 
contains a puromycine resistance cassette. For further details see Ketteler et al. (128). 
Table 2-1: Plasmids used in this study. 
name promoter transgene description 
gp130 vectors 
p409 SV40 L-gp130 The constitutive active variant L-gp130 is expressed 
under control of the SV40 promoter. 
p409 SV40 eYFP- 
gp130 wt 
The wildtype variant of gp130 is fused N-terminally to 
eYFP and expressed under control of the SV40 
promoter. 
p409 SV40 eYFP- 
gp130 ΔYY 
A constitutive active deletion mutant of gp130 
(del Y186-Y190) is fused N-terminally to eYFP and 
expressed under control of the SV40 promoter. This 
mutant is explained in detail in section 4.1.3. 
Other 
pcDNA3.1 hCMV GFP The green fluorescent protein (GFP) is expressed 
under control of the human cytomegalovirus (hCMV) 
promoter. 
pcDNA3.1 hCMV myc- SOCS3 The suppressor of cytokine signaling (SOCS) 3 is fused 
N-terminally to c-myc and expressed under control of 
the human cytomegalovirus (hCMV) promoter. 
pMOWs 5’MFG/MESV myc-gp130 Different mutants of gp130 are fused N-terminally to 
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LTR c-myc and are expressed under control of 
5’MFG/MESV LTR. 
pMOWs 5’MFG/MESV 
LTR 
GFP The green fluorescent protein (GFP) is expressed 
under control of 5’MFG/MESV LTR. 
TK-RL Thimidin 
kinase 
Renilla 
luciferase 
Renilla luciferase is expressed under control of the 
promoter for the thimidin kinase. 
SIEM-Luc STAT3 
senstive 
promoter 
Firefly 
luciferase 
Firefly luciferase is expressed under control of a 
STAT3 sensitive promoter. 
Tet-vectors 
pBI5-L-
gp130 
TRE L-gp130/ 
Firefly 
luciferase 
The constitutive active variant L-gp130 and the 
reporter gene firefly luciferase are expressed under 
control of the tetracycline responsive promoter 
element (TRE). L-gp130 is explained in detail in 
section 1.8. 
pBI5-GFP TRE GFP The Green Fluorescent Protein (GFP) is expressed 
under control of the tetracycline responsive promoter 
element (TRE). 
pTan-Pur TRE tTA The tetracycline transactivator protein (tTA) is 
expressed under control of the tetracycline responsive 
promoter element (TRE). 
pUHD 15-1 hCMV tTA The tetracycline transactivator protein (tTA) is 
expressed under control of the human cytomegalovirus 
(hCMV) promoter. 
pUHD 15-30 Lap tTA The tetracycline transactivator protein (tTA) is 
expressed under control of the promoter of the liver 
enriched activator protein (Lap). 
pUHD 17-1 hCMV rtTA The reverse tetracycline transactivator protein (rtTA) is 
expressed under control of the human cytomegalovirus 
(hCMV) promoter. 
pUHD 61-30 Lap rtTA The reverse tetracycline transactivator protein (tTA) is 
expressed under control of the promoter of the liver 
enriched activator protein (Lap). 
pMOWs 5’MFG/MESV 
LTR 
tTA The tetracycline transactivator protein (tTA) is 
expressed under control of 5’MFG/MESV LTR. 
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2.4.2 Oligonucleotides 
Oligonucleotides were synthesized by Metabion and Sigma-Aldrich. 
Table 2-2: Primers used in this study. 
Name Sequence 5’-3’ 
Myc tag 
AgeI-myc-NotI sense 5’-CCGGTCGCCACCGAACAAAAACTCATCTCAGAAGAGGATCTGT
AGGC-3’ 
AgeI-myc-NotI antisense 5’-GGCCGCCTACAGATCCTCTTCTGAGATGAGTTTTTGTTCGGT
GGCCA-3’ 
Gp130 sequencing primers 
gp130_N-term 5’-GGCCTGAGTGAAACCCAATG-3’ 
gp130_N-term_reverse 5’-TGACACTGGATGCTGTTCTG-3’ 
gp130_SP 5’-TCGCCGCCATGTTGACGT-3’ 
gp130_muta 5’-ACAATAATTTCGGGCTTG-3’ 
Mutagenesis primers 
gp130 C172S sense 5’-CACACAAGTTTGCTGATAGCAAAGCAAAAC-3’ 
gp130 C172S antisense 5’-CGTTTTGCTTTGCTATCAGCAAACTTGTGTG-3’ 
gp130 V189G sense 5’-GATTATTCTACTGGGTATTTTGTCAAC-3’ 
gp130 V189G antisense 5’-GTTGACAAAATACCCAGTAGAATAATC-3’ 
gp130 Y190G sense 5’-GATTATTCTACTGTGGGTTTTGTCAACATTG-3’ 
gp130 Y190G antisense 5’-CAATGTTGACAAAACCCACAGTAGAATAATC-3’ 
gp130 D215G sense 5’-CATATCAATTTTGGTCCTGTATATAAAGTG-3’ 
gp130 D215G antisense 5’-CACTTTATATACAGGACCAAAATTGATATG-3’ 
gp130 V252G sense 5’-CAAGTATTAAGAGTGGTATAATACTAAAATATAAC-3’ 
gp130 V252G antisense 5’-GTTATATTTTAGTATTATACCACTCTTAATACTTG-3’ 
Primers for gp130 deletions 
ΔYYΔD1 sense 5’-TTGCCTCCAGAAAAACCTAAAAATTTG-3’ 
ΔYYΔD1 antisense 5’-ATCTAGAAGTTCACCTGTAGATTCAGTGGTG-3’  
ΔYYΔE1-P5 sense 5’-TGTGGTTATATCAGTCCT-3’ 
ΔYYΔE1-P5 antisense 5’-ACCTGTAGATTCAGTGGT-3’ 
Primers for mice genotyping 
tTA sense (856) 5’-CGCTGTGGGGCATTTTACTTTAG-3’ 
tTA antisense (857) 5’-CATGTCCAGATCGAAATCGTC-3’  
rtTA sense 5’-CCATGTCTAGACTGGACAAGA-3’ 
rtTA antisense 5’-CTCCAGGCCACATATGATTAG-3’ 
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TET sense 5’-AATGAGGTCGGAATCGAAGG-3’ 
TET antisense 5’-TAGCTTGTCGTAATAATGGCGG-3’ 
L-gp130 full length sense 5’-CCACCATGTTGACGTTGC-3’ 
L-gp130 full length 
antisense 
5’-TCACTGAGGCATGTAGCC-3’ 
luciferase sense 5’-AGGACCTATGATTATGTCCGGTTA-3’ 
luciferase antisense 5’-GTACTTCGTCCACAAACACAACTC-3’ 
Primers for gp130 probe (Southern blot) 
L-gp130 probe sense 5’-ACCTTGAAAGCTCAGAACTCGG-3’ 
L-gp130 probe antisense 5’-GGTAGACTCGGATCTTGAGAAG-3’ 
RT-PCR 
Oligo dT 5’-TTTTTTTTTTTTTTTTTT-3’ 
2.5 Antibodies 
Specific antibodies were used for protein detection in Western blot analysis, in immunoprecipitation 
studies and in flow cytometry according to manufacturer’s protocol. 
2.5.1 Primary antibodies 
Primary Antibodies were diluted 1: 1000 in NETG for Western blot analysis. For immunoprecipitation 
studies the antibodies anti-GFP and anti-myc were used at a final concentration of 0.8 µg. For flow 
cytometry analysis the anti-gp130 antibody B-P4 (100 µg/ml) was used at a final concentration of 
50-100 ng/ 1x106 cells. Inhibition studies with proliferating Ba/F3-gp130 cells were conducted with the 
anti-gp130 antibodies B-P4 (100 µg/ml) or C-20 (200 µg/ml) at a final concentration of 1 µg/ml. 
 
Cell Signaling  
anti -Phospho-STAT3 (D3A7)XP™ rabbit monoclonal antibody recognizes human, mouse and rat 
#9145   STAT3 only if phosphorylated at residue Tyr705.  
anti-STAT3    mouse monoclonal antibody recognizes human, mouse, rat and 
#9139   monkey STAT3. 
anti-P-Tyr-100    mouse monoclonal antibody recognizes phosphorylated tyrosine 
#9411   residues.  
  
Material 
 
26 
 
Roche  
anti-GFP    mouse monoclonal antibody recognizes the green fluorescent 
Cat.No. 11 814 460 001   protein (GFP) (Aequorea victoria), GFP derivatives such as e.g. 
YFP and EYFP.  
Santa Cruz  
anti-c-Myc (9E10)   mouse monoclonal antibody recognizes human, mouse and rat 
sc-40    c-myc protein as well as Myc-tag, raised against the epitope 
EQKLISEEDLN.  
anti-gp130 (B-P4)    mouse monoclonal antibody recognizes the extracellular domain 
sc-57188   (D4) of human gp130.  
anti-gp130 (C-20)    rabbit polyclonal antibody recognizes the intracellular  domain 
sc-655   of human, mouse and rat gp130.  
 
anti-VP16 (1-21)    mouse monoclonal antiobody recognizes VP16 and VP16 fusion 
sc-7545   proteins, raised against the epitope corresponding to amino acids 
456-490 of VP16.  
MoBiTech  
anti-TetR(B)    mouse monoclonal antiobody recognizes the Tet-repressor 
TET02   domain.  
Millipore  
anti-P-Y(4G10)    mouse monoclonal antibody recognizes phosphorylated tyrosine 
residues.  
2.5.2 Secondary antibodies 
All secondary antibodies were purchased from Thermo Fisher Scientific and used at a dilution of  1:5000. 
ImmunoPure® Goat anti-rabbit igG, (H+L), Peroxidase Conjungated #31462 
ImmunoPure® Goat anti-mouse igG, (H+L), Peroxidase Conjungated #31432 
Goat-anti-mouse-Dylight 649      #35515 
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2.6 Organisms 
 
2.6.1 Cell lines 
Cell culture dishes and flasks were obtained from Sarstedt. All cells were cultivated at 37°C, 5% CO2 and 
90% relative humidity.  
HepG2 cells and HEK 293T cells are human cell lines and were obtained from the German Resource 
Centre for Biological Material (DSMZ). Parental Ba/F3 cells do not express endogenous gp130 and 
acquired IL-3 as growth factor. Ba/F3-gp130 cells were stably transfected with a cDNA coding for human 
gp130 and grew in dependence of Hyper-IL-6 (explained in section 1.3).  The ecotrophic phoenix cell line 
was used for the production of retroviraly supernatant, which exclusively infects murine cells. 
Table 2-3: Cell lines used in this study. 
HepG2 human  hepatocellular carcinoma cells RPMI + 10% FCS 
HEK 293T human  embryonic kidney cells DMEM + 10% FCS 
Phoenix 
(Eco) 
human HEK 293T cell-derived retroviral packaging cell 
line 
DMEM + 10% FCS 
MEF murine embryonic fibroblasts DMEM + 10% FCS 
Ba/F3 murine pre B-cells (IL-3 dependent) RPMI + 10% FCS 
10 ng/ml mIL-3 
Ba/F3-
gp130 
murine pre B-cells (Hyper-IL-6 dependent) DMEM + 10% FCS 
10 ng/ml Hyper-IL-6 
 
2.6.2 Animals 
Wildtype C57BL/6N mice were purchased from Charles River (Sulzfeld, Germany). Transgenic 
heterozygous L-gp130+ tg mice were generated in the Interfakultäre Biomedizinische Forschungseinrichtung (IBF, 
University of Heidelberg) on a C57BL/6N background. The heterozygous LC-1 tg mice and the 
hCMV-rtTA tg mice (mixed background) were a kind gift of Prof. Dr. Saftig (Department of 
Biochemistry, CAU Kiel). LC-1 tg mice express the Cre-recombinase and firefly luciferase under control 
of a tetracycline-responsive promoter element. hCMV-rtTA+ tg mice express the reverse tetracycline 
transactivator (rtTA) under control of the human cytomegalovirus promoter. Transgenic heterozygous 
Lap-tTA+ tg mice were kindly provided by Lars Zender (Helmholtz Centre for infection research, 
Braunschweig) with NMRI background and were backcrossed to C57BL6/N background up to the 
7th generation. These mice express the tetracycline transactivator (tTA) under control of a liver specific 
promoter. The heterozygous Lap-rtTA+ tg mice (C57BL6/N background) were obtained from the 
European Mouse Mutant Archive (EMMA, Italy). These mice express the reverse tetracycline 
transactivator (rtTA) under control of a liver specific promoter.  
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Table 2-4: Mouse strains used in this study. 
strain transgene  tissue 
specificity 
genetic 
background 
Lap-tTA Tg(Cebpb-rtTA2S*S2)1Bjd  tTA liver, kidney NMRI 
rTALAP-1 Tg(Cebpb-tTA)5Bjd rtTA liver, kidney C57Bl/6N 
hCMV-rtTA Tg(CMV-tTA)4Bjd rtTA ubiquitous mixed 
L-gp130  L-gp130, 
firefly luciferase 
ubiquitous C57Bl/6N 
LC-1 Tg(tetO-cre)LC1Bjd Cre-recombinase, 
firefly luciferase 
ubiquitous mixed 
2.7 Kits 
All kits were used according to the manufacturer’s protocol. 
Fermentas GeneJET™ Plasmid Miniprep Kit 
GE Healthcare ECL-Plus 
 ProbeQuantTM G-50 Micro Columns 
Invitrogen Mouse-SAA ELISA (Catalog Number KMA0021) 
Macherey Nagel NucleoSpin® RNAII (740955.250) 
 NucleoSpin® RNA/Protein (740933.10) 
 Nucleobond® XtraMidi (740410.100) 
Pierce BCA Protein Assay Reagent 
 Super Signal ® West Pico Chemiluminescent Substrate 
Promega Dual-Glo® Luciferase Assay System (E2920) 
 Luciferase Assay System (E1500) 
Quiagen Gentra Puregene Tissue Kit 
 QIAquick Gel Extraction Kit 
 QIAquick PCR Purification Kit  
Stratagene Prime-It II Random Primer Labeling Kit 
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3 METHODS 
3.1 Molecular biology methods 
 
3.1.1 Transformation of bacteria 
10 - 100 ng of plasmid DNA or 5 µl of a ligation reaction was mixed with 10 µl of 5x KCM buffer in a 
total volume of 50 µl, added to 50 µl of chemical-competent E.coli DH5α and incubated for 30 min on ice. 
Bacteria were heat-shocked (42°C, 1 min), subsequently chilled on ice for 5 min and were then incubated 
with 500 µl LB w/o antibiotics for 1 h at 37°C under constant agitation. Bacteria were centrifuged (5 min, 
6,000 x g) and supernatant was discarded. The pelleted bacteria were resuspended in 100 µl of the 
remaining LB media and spread on LB-agar plates with the indicated antibiotics. Plates were incubated at 
37°C overnight. 
3.1.2 Plasmid isolation  
For plasmid preparation of transformed bacteria a single colony was inoculated in 2 ml LB medium with 
appropriate antibiotic and incubated at 37°C, under constant agitation over night. The bacteria cultures 
were pelleted by centrifugation (2 min, 6,000 x g). Isolation of DNA was done using the GeneJET™ 
Plasmid Miniprep Kit according to the manufacturer’s protocol (Fermentas). The DNA pellet was dried 
for 10 min at 37°C and dissolved in 100 μl ddH2O. DNA was analyzed by restriction digestion and 
verified by sequencing. 
To prepare large amount of purified DNA, 100 ml bacterial cultures were inoculated and plasmid DNA 
was isolated using the Nucleobond® XtraMidi kit (Macherey Nagel) according to the manufacturer’s 
protocol.  
3.1.3 Digestion, blunting and dephosphorylation of vector DNA 
The digestion of vector DNA and of PCR fragments was performed with the appropriate digestion 
enzyme at 37°C for 1 – 3 h according to the manufacturer’s protocol (Fermentas). The enzymatic reaction 
was stopped at 65°C for 20 min. PCR fragments were purified using the QIAquick PCR Purification Kit 
(Quiagen), whereas vector DNA was purified via QIAquick-gel extraction kit (Qiuagen). The digested 
DNA-ends were filled by Klenow reaction (10 min, 37°C and 10 min, 75°C). For dephosphorylation 1 U 
calf instestinal alkaline phosphatase (CIAP) was added to the digested vector and the reaction was 
incubated for 30 min at 37°C followed by heat inactivation. Finally, the samples were loaded onto an 
agarose gel and purified using a QIAquick-gel extraction kit (Qiuagen). 
  
Methods 
 
30 
 
3.1.4 Ligation of DNA fragments 
Purified PCR fragments were ligated into digested, linearized plasmids (100 ng) using T4 DNA ligase 
(Fermentas) with five-fold molar excess of the insert according to the manufacturer’s protocol. The 
reaction was incubated either at room temperature (RT) for 3 - 4 h or for 1h at RT following incubation at 
16°C over night. 
3.1.5 Purification of DNA fragments 
For isolation and purification of DNA fragments from agarose gels, ethidium bromide stained gels were 
illuminated with UV-light. The appropriate DNA band was excised from the gel with a clean scalpel and 
transferred into a 1.5 ml tube. The DNA fragment was isolated by using the QIAquick-gel extraction Kit 
(Qiagen) following the manufacturer’s instructions. 
Purification of PCR fragments was done with the QIAquick PCR Purification Kit (Qiagen) according to 
the manufacturer’s protocol. 
3.1.6 Optimization of the Kozak sequence of pBI5-L-gp130 
To achieve the best translation of the transgene L-gp130, the Kozak sequence was optimized from 
CUACC to CCACC. Therefore, L-gp130 was amplified via PCR using specific primers containing the new 
Kozak sequence as well as the restriction sites for NheI and Hind III (Fig 3.1, Tab. 3-1). 
 
Figure 3.1: Primer binding sites for the introduction of a new Kozak sequence and restriction 
sites in the sequence of L-gp130. The restriction enzymes EcoRI and PstI were used to verified the 
orientation of the insert. 
The vector pBI5 and the purified PCR fragment were digested by the restriction enzymes NheI and 
HindIII. The vector backbone was subsequently dephosporylated with CIAP to prevent re-ligation. 
Vector and PCR fragment were ligated and transformed into chemical-competent bacteria. Following 
successful transformation the DNA was isolated and the orientation of the insert was verified by digestion 
with the restriction enzymes EcoRI or PstI. Digestion with EcoRI resulted in four specific fragments 
(278bp, 563 bp, 1.609 bp, 4.796 bp) and digestion with PstI generated three specific fragments (161 bp, 
1.488 bp, 5.597 bp). 
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Table 3-1: Primers for L-gp130 containing the new Kozak sequence (bold text) and the 
restriction sites for NheI and HindIII  (underlined). 
3.1.7 Cloning of pMOWs-tTA 
The retroviral vector pMOWs-GFP was digested with EcoRI and EcoNI to remove the sequence coding 
for GFP. 5’-overhangs were filled via Klenow reaction to obtain a blunt ended vector. The vector pTan-
Pur contains the sequence for the tetracycline transactivator (tTA) and was digested with HindIII and 
SpeI. The tTA fragment was purified via gel extraction and 5’-overhangs were filled via Klenow reaction. 
The blunted vector backbone of pMOWs and the blunted tTA fragment were ligated and transformed 
into chemical-competent bacteria. Following successful transformation the DNA was isolated and the 
orientation of the insert was verified by digestion with the restriction enzyme XbaI, which cuts the insert 
and the vector backbone. If the inserted tTA fragment is in the correct orientation, a fragment size of 
1200 bp is expected, whereas a fragment size of 2200 bp identifies an incorrect orientation of tTA into the 
vector. 
3.1.8 Generation of myc-tagged constructs 
The expression construct p409-eYFP-gp130 was digested with AgeI and NotI to remove the sequence 
coding for eYFP and dephosphorylated using 1 U of FastAP™ (Fermentas) to prevent re-ligation. 
Oligonucleotides containing the sequence coding for the myc-tag (f.c. 3 mg/ml) were annealed in 
NEBuffer4 and phosphorylated using T4 polynucleotide kinase (Fermentas) according to the 
manufacturer’s protocol. The annealed and phosphporylated myc-oligonucleotides were then ligated with 
the digested and dephosphorylated plasmid using T4 DNA ligase (Fermentas) at RT for 1 h and 16°C 
over night. The ligation mixture was transformed into chemical-competent E.coli DH5α bacteria, followed 
by plasmid isolation and sequencing. 
3.1.9 Quantification of nucleic acids and sequencing 
DNA and RNA concentrations were determined spectrophotometrically using Nano-Drop (PeqLab) 
technology by measuring the absorbance at 260 nm, 280 nm and 320 nm. 
DNA sequencing was performed by SeqLab (Göttingen) and GATC Biotech AG (Köln) using single read 
sequencing by Sanger. 
3.1.10 DNA gel electrophoresis 
1% (w/v) agarose gels were prepared by heating of 1 g agarose (Biozym) in 100 ml of 0.5x TBE buffer 
supplemented by 0.05% (v/v) ethidium bromide. DNA sample was diluted with 6x DNA sample buffer 
L-gp130 sense NheI 5’-CTGAGCTAGCCCACCATGTTGACGTTGCAGAC-3‘ 
L-gp130 antisense HindIII 5’-CAAGGCGGCTACATGCCTCAGTGAAAGCTTCTGA-3‘ 
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and loaded onto the agarose gel. DNA fragments were separated depending on their size, by horizontal 
agarose gel electrophoresis at constant voltage (100 V). Gel documentation was performed at the BioDoc 
system (Biometra). 
3.1.11 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) was used to amplify DNA sequences either for cloning or for detection. 
DNA for cloning was amplified using Pfu polymerase (Fermentas), while DreamTaq-polymerase 
(Fermentas) was used for detection of specific DNA sequences according to the manufacturer’s protocol. 
The following reaction mixture was used for the different applications:  
Template 10 – 100 ng plasmid DNA or 1 µl of cDNA 
Forward primer 10 pmol 
Reverse primer 10 pmol 
dNTPs 10 mM each  
PCR buffer (10x) 5 µl  
Polymerase 1 U 
ddH2O  ad 50 µl 
The PCR was performed according to the following scheme:  
95°C 5 min  initial denaturation 
95°C 45 sec  denaturation 
55°C – 61°C* 45 sec  primer annealing  30 cycles 
72°C 1 min/1kb elongation (1 min/1kb) 
72°C 5 min  final elongation 
*Primers used for different approaches required varying annealing temperatures. 
3.1.12 Site directed mutagenesis PCR 
Single amino acid exchange was performed via mutagenesis PCR. The point mutations were created by 
designing a mismatch in the mutagenic primer. For generating point mutations, the length of the correctly 
matched sequence in the mutagenic primers should be in average 24−30 nucleotides. The desired 
mutation should be in the middle of the primer with 10−15 perfectly matched nucleotides on each side. 
The reading frame must not be altered. Phusion® high fidelity polymerase (NEB) was used according to 
the manufacturer’s protocol (Fermentas). The following reaction mixture was used with 50 ng template 
DNA for the different applications:  
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Template 50 ng plasmid DNA 
Forward primer 10 pmol 
Reverse primer 10 pmol 
dNTPs 10 mM each  
HF buffer (5x) 10 µl  
Polymerase 1 U 
ddH2O  ad 50 µl 
The PCR was performed according to the following scheme:  
95°C 3 min   initial denaturation 
95°C 20 sec   denaturation 
44°C – 55°C* 20 sec   primer annealing 20 cycles 
72°C 30 s/1 kb  elongation  
72°C 5 min   final elongation 
*Primers used for different approaches required varying annealing temperatures. 
Following PCR the non-mutated template vector was eliminated by digestion using the enzyme DpnI 
(37°C for 1 h, 80°C for 20 min), which exclusively digests methylated DNA. To verify the PCR, samples 
were analyzed on a 0.8% agarose gel and PCR products were transformed into bacteria E.coli DH5α, 
followed by plasmid isolation and sequencing. 
3.1.13 Deletion PCR 
Deletions are created by designing primers that border the deleted area on both sides. To generate a 
deletion, the primers should be perfectly matched on their entire length, which should be 24−30 
nucleotides. The primers must be phosphorylated at the 5’ end to ensure that the new generated plasmid 
can ligate after deletion PCR. The phosphorylation reaction was done using T4 kinase (Fermentas) 
according to the manufacturer’s protocol. The reaction mixture was incubated for 20 min at 37°C and 
10 min at 75°C and was subsequently used for mutagenesis PCR (1 ng template DNA, see 3.1.2), followed 
by ligation. Unchanged DNA was digested by DpnI as described above. 
3.1.14 RNA Isolation 
The NucleoSpin RNA II kit (Macherey-Nagel) was used for the isolation of ribonucleic acid (RNA) from 
different tissues and cells, e.g. 15 mg of liver tissue according to the manufacturer’s instructions. 1 μg of 
total RNA was used as a template for the reverse transcription (RT-PCR) to generate cDNA. 
3.1.15 Reverse transcription PCR (RT-PCR) 
1 µg messenger RNA was reverse transcribed into complementary DNA (cDNA) using the reverse 
transcriptase. The generated single-stranded cDNA was further used for PCR analysis. The M-MuLV 
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Reverse Transcriptase (20 U/µl) or the RevertAid™ Reverse Transcriptase (200 U/µl) was used according 
to the manufacturer’s protocol. The reaction was performed using oligo (dT)18 primer, which anneal at the 
3’ poly (A) mRNA tail. 1 μl of the generated cDNA was used for the beta-actin (housekeeping gene) PCR 
as well as for a specific transgene PCR. 
3.1.16 Protein extraction 
Liver samples (30 – 50 mg) were homogenized in 500 μl tissue lysis buffer using ceramic beads. The 
amount of lysis buffer was adjusted to other organs. After homogenization with the Precellys® tissue 
homogenizer (Peqlab) the samples were incubated at 4°C under constant agitation for 1 h and 
subsequently cleared by centrifugation (15 min, 12,000 x g). The supernatant was transferred into a new 
tube and stored at -20°C. 
3.1.17 Quantification of protein concentration  
Protein concentration of tissue lysates was determined using the BCA kit (Pierce) according to the 
manufacturer’s protocol. The protein concentration was calculated based on the extinction measured at 
562 nm in a microtiter plate reader (Tecan).  
3.1.18 SDS-polyacrylamide gel electrophoresis 
Proteins were separated by discontinuous SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using the 
Mini-PROTEAN system (BioRad). Protein samples were supplemented with 5x Laemmli buffer and 
loaded onto the gel. Electrophoresis was performed in 1x SDS running buffer and was carried out at 
120-180 V for 90 to 120 min.  
3.1.19 Western blot 
Proteins separated by SDS-PAGE were transferred onto a PVDF membrane (GE Healthcare) using the 
wet blot Mini Trans-Blot Cell apparatus (BioRad) for 120 min (90 V, 4°C). Subsequently, the PVDF 
membrane was blocked with NETG at RT for 1h and incubated with the primary antibody diluted in 
NETG. After incubation at 4°C over night, the membrane was washed three times with NETG for 
10 min and the appropriate secondary antibody linked to peroxidase (POD) was diluted in NETG and 
applied at RT for 1 h. The membrane was washed three times for 10 min with NETG to be subsequently 
developed using ECL Kit. The chemoluminescent signals were detected with the CCD camera system 
LAS-1000 (Fujifilm) or FluorChem®Q (Alpha Innotech). To analyze different proteins on the same 
membrane, the bound antibodies were removed by using an acidic mild stripping buffer. After the 
stripping procedure the membrane was washed several times with water, blocked again with NETG and 
was incubated with another primary antibody. 
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3.1.20 SAA-ELISA  
The enzyme-linked immunosorbent assay (ELISA) was used to detect and quantify the amount of serum 
amyloid A (SAA) in mouse sera. The serum samples were diluted 1:20. The specific murine SAA-ELISA 
(Invitrogen) included an internal purified standard and was done according to the manufacturer’s 
protocol. Quantification of the reaction was done by measuring the ELISA in a microtiter plate reader 
(Tecan) at 450 nm. 
3.1.21 Southern blot 
To detect specific DNA sequences in a sample, a single-stranded labeled DNA probe is used, which 
anneals to the gene or DNA fragment of interest. Therefore, genomic DNA was extracted from tail 
biopsy and 5 to 10 µg of genomic DNA was digested with NheI and XbaI (3 µl, 20 U/µl) at 37°C over 
night. The next day DNA was separated on a 0.7% agarose gel (4-6 h, 60 V) and subsequently depurinated 
with 0.25 M HCl for 15 min. Double stranded DNA was denatured for 30 min under alkaline conditions 
to improve the binding capacity of the negatively charged DNA to the positively charged nylon membrane 
(Amersham Hybond N+, GE healthcare). The single stranded DNA hybridizes better with the 
radioactively labeled probe at low pH.  
Table 3-2: Protocol for Southern blot analysis. 
Depurination depurination buffer 1x 15 min 
Denaturation denaturation buffer 2x 15 min 
Neutralization neutralization buffer 1x 10 min 
Washing  10x SSC 1x 5 min 
Blotting  10x SSC over night 
Washing  5x SSC 1x 15 min 
Baking  10 min, 65°C 
Cross-linking UV 2 min 
Pre-hybridisation 20 ml churchbuffer 1 h, 65°C 
Labeling (DNA probe) Prime-It II Random Primer Labeling Kit 
Purification (DNA probe) ProbeQuantTM G-50 Micro Colums 
Hybridization  Probe preparation 5 min, 95°C 
chill on ice 
 20 ml churchbuffer (pre-warmed) 
add 50 µl radioactive probe 
overnight, 65°C 
 
 discard hybridization solution  
Washing 2x SSC + 0.1% SDS short time shaking 
 2x SSC + 0.1% SDS 2x 15 min, 65°C 
 0.1x SSC + 0.1% SDS 2x 10 min, 65°C 
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 2x SSC 1x short time shaking 
Shrink-wrap in foil   
Stripping (membrane) 0.5% SDS  
The nylon membrane was labeled and placed below the gel. Several sheets of filter paper as well as a stack 
of paper towels were put on the top of the gel. Pressure was exerted by additional weights (1-2 kg).  The 
whole sandwich was assembled according to Fig. 3.2.  
 
Figure 3.2: Performance of Southern blot analysis. (A) Restricted DNA was fragmented on an 
agarose gel, depurinated and denatured followed by blotting to a nylon membrane. (B) DNA was 
cross-linked to the nylon membrane by UV light and hybridized with a radioactively labeled probe. 
The labeld membrane was analyszed via a Phosphorimager (Fuji).  
This stack was built on a glass bridge above a pan filled with buffer (10x SSC). A long filter paper bridge 
was used to connect the buffer with the membrane to prevent its dehydration. Due to capillary flow the 
DNA migrated from the gel to the membrane. The DNA bound to the membrane via ionic interactions. 
The transfer was performed at room temperature over night. The next day the membrane was washed and 
baked for 10 min at 65°C. The membrane was irradiated with UV light for 2 min to crosslink the DNA to 
the membrane and was pre-incubated with warm Church buffer using a glass container. Finally the 
membrane was hybridized with a radioactively labeled probe. To detect transgenic DNA, a specific probe 
for L-gp130 was generated using PCR with specific primers, which generated a 600 bp fragment of 
L-gp130. This PCR product was labeled with α-32P or α-33P-dATP using the Primer Labeling Kit 
(Stratagene) according to the manufacturer’s protocol. The purification of radioactive labeled probe was 
done with ProbeQuantTM G-50 Micro Colums (GE Healthcare) according to the manufacturer’s protocol. 
Analysis of the radioactive labeled membrane was done with a Phosphorimager (Fuji). 
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3.2 Cell culture methods 
 
3.2.1 Conditions 
Cell culture was conducted in flasks with the corresponding culture medium. Cells were passaged 
following confluency. For HEK 293T and phoenix cells it was sufficient to flush them vigorously with 
culture medium to detach them from the culture dish. In order to detach HepG2 cells, they were washed 
once with 1 ml trypsin and subsequently trypsinized in 2 ml trypsin at 37°C. Trypsinization was stopped 
with the addition of culture medium. 
The detached cells were centrifuged (1,000 x g, 5 min) and the pellet was resolved in fresh medium. The 
cells were passaged in a ratio of 1:10 or seeded in dishes or 6-well plates for transfection at a ratio of 
4 - 8x 105 cells/well. Suspension cells were split by transferring an appropriate amount of the cells into a 
new flask containing medium and the corresponding cytokine. 
3.2.2 Transient transfection 
Cells were seeded at a density of 4 – 8x 105 cells/well the day before transfection. Turbofect™ 
(Fermentas) was used to indroduce plasmid DNA into the cells according to the manufacturer’s protocol. 
Medium of the cells was changed before the transfection. The appropriate amount of plasmid DNA 
(1 - 5 µg) was diluted in serum free medium (SFM) and a twofold amount of Turbofect™ was added. 
Following 15 - 20 min of incubation at RT this mixture was added drop wise to the cells, followed by an 
incubation period of 24 - 48 h at 37°C. 
3.2.3 Starving and stimulation 
Transfected cells were washed once and starved in serum free medium (SFM) in medium containing 
0.5% FCS for 4 - 5 h or overnight. When indicated, cells were stimulated with 10 ng/ml of Hyper IL-6 for 
10 to 15 min before cell lysis. 
3.2.4 Retroviral transduction 
Ba/F3 as well as mEF cells were transduced according these instructions. Prior, target cells were seeded 
and subjected to different puromycin concentrations ranging from 0.5 µg – 5 µg/ml to determine the 
lethal dosis. Phoenix cells were plated in 6-well plates at a cell density of 8x 105 cells/well and were 
transiently transfected with pMOWs retroviral expression constructs containing myc-tagged gp130 
variants or tTA on the next day. pMOWs-GFP served as an appropriate control for transfection and 
transduction efficiency. 24 h after transfection the supernatant containing the retroviral particles was 
collected and filtered through a 0.2 µm pore size filter. 
Ba/F3 cells were diluted to a cell number of 2x 106 cells/ml and 50 µl (1x 105 cells) were mixed with 
250 µl of the corresponding supernatant. Polybrene was added at a final concentration of 8 µg/ml and 
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cells were centrifuged (2,000 x g) at RT for 2 h. The supernatant was discarded and the remaining pellet 
was resuspended in 5 ml medium containing the respective cytokine. 
mEF cells were seeded at a densitiy of 4x 105 cells/well in a 12-well plate one day before transduction. 
The medium was removed and 1 ml of the filtered supernatant was supplemented to the cells and mixed 
with polybrene. Following centrifugation (2,000 x g) for 2 h at RT, 1 ml medium was added to the cells to 
dilute the supernatant. 
48 h post transduction, cells were selected with puromycin at a final concentration of 1 – 1.5 µg/ml for 
Ba/F3 cells. mEF cells showed a higher resistance and were selected with 3 µg/ml of puromycin. 
3.2.5 Surface expression analysis via flow cytometry 
Ba/F3 cells were pelleted and washed once with PBS (5 min, 1,000 x g). Cells were resuspended in 1 ml 
PBS containing 5% FCS, counted using a hemocytometer and subsequently diluted to 1x 106 cells in 50 µl 
PBS+5%FCS. To block unspecific binding sites, 0.5 µl of rat-anti-mouse CD16/CD32 (Fc-block, BD) 
was added and incubated at RT for 5 min. Following blocking, cells were incubated with anti-gp130 
antibody B-P4 (50 ng) at RT for 60 to 90 min. The cells were washed twice with 1 ml PBS+5%FCS, 
followed by incubation with the secondary antibody goat-anti-mouse-DyLight 649 (500 ng) for 30 to 60 
min at 4°C in the dark. For the measurement cells were washed twice with 1 ml PBS+5%FCS and 
resuspended in 500 µl PBS 5%FCS. Analysis was performed on a BD FACSCanto. 
3.2.6 Intracellular expression analysis via flow cytometry 
Ba/F3 cells were adjusted to 1x 106 cells, washed once with PBS containing Ca2+and Mg2+ (5 min, 
1,000 x g) and resuspended in 0.5 ml PBS (Ca2+, Mg2+). Cells were fixed by adding 0.5 ml fixation buffer 
and gently mixing (20 min, RT). Cells were subsequently washed once with PBS (Ca2+, Mg2+), once with 
permeabilization buffer and once with super permeabilization buffer. The primary antibody 
(anti-gp130: B-P4) was used in twofold amount compared to surface staining (100 ng) and was incubated 
for 30 min at RT. Then the cells were washed twice with permeabilization buffer and incubated with the 
secondary antibody anti-mouse-DyLight 649 (500 ng) at 4°C in the dark for 30 min. Cells were then 
washed twice with permeabilization buffer, once with PBS (Ca2+, Mg2+), once with staining buffer and 
were finally resuspended in 500 µl staining buffer. Analysis was performed on a BD FACSCanto. 
3.2.7 STAT3 reporter assay 
To measure the transcriptional activity of STAT3, we used a STAT3 reporter construct in which firefly 
luciferase is expressed under the control of a STAT3 responsive promoter element (SIEM-Luc) 
(123, 129). A construct expressing renilla luciferase (TK-RL) was used to control the transfection 
efficiency. HepG2 cells were seeded at a density of 4 - 8x 105 cells/well in a 6-well plate. Next day the cells 
were co-transfected with 1 µg SIEM-Luc, 1 µg TK-RL and 1 µg of the p409-eYFP gp130 construct. The 
cells were analyzed for YFP expression using fluorescence microscopy. Following starvation cells 
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expressing gp130 wt were stimulated with Hyper-IL6 (10 ng/ml) for 4 h. Then the cells were washed with 
PBS and lysed using the passive lysis buffer of the DualGlo® luciferase Kit (Promega). Luciferase activity 
was measured according to the manufacturer’s protocol.  
3.2.8 Dual luciferase assay 
The Dual-Glo® Kit (Promega) was used to measure firefly and renilla luciferase simultaneously according 
to the manufacturer’s instructions. The bioluminescence was detected in a white 96-well plate using a plate 
injector system (GLOMAX®). 20 µl of cell lysates were dispensed per well and the injector added 50 µl of 
the first substrate D-luciferin per well. The firefly luciferase luminescence was quenched by adding 50 µl 
of the Stop&Glo Reagent to the sample after quantitation. This reagent includes coelenterazine and 
subsequently the renilla luciferase luminescence was quantified. A 2 sec premeasurement delay followed by 
a 10 sec measurement period for each reporter was performed. All samples were measured in duplicates or 
triplicates and were stored at -20°C. 
3.2.9 Luciferase assay 
The activity of firefly luciferase was measured in cell lysates and tissue homogenates using the Luciferase 
Assay System Kit (Promega) according to the manufacturer’s protocol. The bioluminescence was detected 
in a white 96-well plate using a plate injector system (GLOMAX®). Murine liver sections (30 mg, median 
lobe) were homogenized in 500 µl 1x lysis reagent (CCLR, 4°C). 20 µl of cell lysates were dispensed per 
well and the injector added 50 µl of the substrate D-luciferin per well. A 2 sec premeasurement delay 
followed by a 10 sec measurement period was performed to quantify the firefly luciferase luminescence. 
All samples were measured in duplicates or triplicates and were stored at -20°C. 
3.2.10 MTT cell viability assay 
Proliferation of Ba/F3-gp130 cells stably transduced with the gp130 constructs was detected in the 
absence or presence of cytokines, inhibitors or antibodies by the MTT viability assay. The cells were 
washed three times (1,000 x g, 5 min) with PBS and resuspended in 1 ml appropriate medium for 
counting. Cells were resupendend in serum free medium containing the appropriate supplement and 
seeded with a density of 5x 103 cells/100 µl in a 96-well plate. Cells treated with 10 ng/ml of Hyper-IL-6 
and 500 nM of the JAK inhibitor Pyridone 6 (P6) were used as controls. Inhibition studies were 
conducted with 1 µg/ml of either B-P4 or C-20 anti-gp130 antibody. Cells were incubated at 37°C for 72 
h. To quantify proliferation 10 µl of the substrate MTT (5 mg/ml) were added and incubated for 
additional 4 h at 37°C. In living cells the MTT was reduced to insoluble purple formazan crystals, which 
were dissolved by adding 100 µl solubilization buffer followed by an incubation at 37°C over night. 
Finally, absorption was measured at 595 nm at microtiter plate reader (Tecan). The proliferation was 
calculated as fold induction. All experiments were made in triplicates or up to 8 times.  
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3.2.11 Cell lysis 
Prior to lysis, cells were washed once in 1 ml PBS. If adherent cells were loosely attached, they were 
scraped into PBS, centrifuged at 2,000 x g for 5 min and subjected to cell lysis. Cells were lysed for 10 min 
on ice. Cell lysates were cleared by centrifugation at 12,000 x g for 15 min at 4°C. 
3.2.12 Co-/Immunoprecipitation 
Cells were lysed either in RIPA-buffer (Ba/F3 cells) or Co-IP buffer (HEK 293T cells). 
Immunoprecipitation was performed by the addition of 0.8 µg antibody (anti-GFP or anti-myc) and 30 µl 
washed protein G sepharose and incubated on a rotating wheel over night at 4°C. Sepharose beads were 
washed three times with 1 ml Co-IP-buffer (3,500 x g, 2 min) and the supernatant was completely 
removed using a Hamilton syringe. Beads were boiled in 30 µl of 2x Laemmli buffer and subsequently 
analyzed by SDS-PAGE. 
3.2.13 Determination of doxycycline concentration in mouse serum 
The serum concentration of doxycycline was analyzed in vitro. Therefore, HEK 293T cells were 
co-transfected with pBI5-L-gp130 and either hCMV-rtTA (Tet-on) or hCMV-tTA (Tet-off). Transfected 
cells were split onto 12-well plates 24 h after transfection. 24 h later 2 µl (for Tet-off) to 10 µl (for Tet-on) 
serum of Dox-treated mice as well as control serum of untreated mice was added to the cells. A defined 
doxycycline concentration was used as control. The cells were lysed 24 h later in luciferase lysis buffer 
(Promega) and luciferase activity was analyzed as described above. 
3.3 Animal methods 
All mice were bred at a 12-h light-dark cycle under standard conditions and provided with food and water 
ad libitum. 
3.3.1 Generation of transgenic mice 
The bidirectional vector pBI5, expressing the constitutive active variant L-gp130 and the reporter gene 
firefly luciferase, was chosen to generate transgenic mice. The plasmid was linearized by digestion with the 
enzyme PvuI and purified via gel extraction. 6 µg purified linearized DNA was sent to the Interfakultäre 
Biomedizinische Forschungseinrichtung (IBF, Heidelberg), where the pronucleii injection and implantation in 
C57BL/6N mice as well as the breeding of the foster mothers were performed. Genomic DNA was 
isolated from the tails of the offspring and genomic insertion of the gene cassette containing L-gp130 and 
firefly luciferase was analyzed via genotyping PCR. 
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3.3.2 Doxycycline treatment 
Doxycycline was supplied either in drinking water containing 3% sucrose or via food pellets. The 
concentration differed in dependence on the mice. For all experiments with Lap-tTA+ tg and LC-1+ tg 
mice (Tet-off) doxycycline was given in low concentrations (Tab.3-3). It has been shown that doxycycline 
passes the placenta and is given to the pups via mother’s milk. Therefore the doxycycline concentration 
was lowered to 1 µg/ml (in drinking water) during breeding, which was shown to suppress activation of 
the Tet-promoter. Mice at the age of 3 weeks received a higher dosage of doxycycline (10 µg/ml) to 
ensure a complete suppression. Later the administration was changed to food pellets containing 
doxycycline (50 mg Dox/kg) due to the better handling. 
For all experiments with hCMV-rtTA+ tg and Lap-rtTA+ tg mice (Tet-on) doxycycline was given in high 
concentrations. Either they got food supplemented with 1 g Dox/kg or doxycycline was given in a 
concentration of 2 mg/ml in drinking water.  
The food pellets were ordered from SNIFF using doxycycline hyclate (Sigma-Aldrich). 
Table 3-3: Supply of doxycycline to the mice. 
Tet-off 1 – 10 µg/ml (3% sucrose) water 
 50 mg/kg food 
Tet-on 1 g/kg food 
 2 mg/ml (3% sucrose) water 
3.3.3 In vivo imaging 
The in vivo imaging of luciferase activity was performed in cooperation with the Molecular Imaging North 
Competence Center (MOIN-CC, UK-SH Kiel) under supervision of Dr. Christian Rosenkranz. 
Initially, the mice were injected i.p. with 10 µl luciferin (15 mg/ml) per g bodyweight to ensure its 
transformation by luciferase and subsequently narcotized with ketamine and xylazine. Luminescence was 
measured with a CCD camera (Berthold NightOWL) for 2 min. 
3.3.4 Isolation of genomic DNA from mouse tail 
Mouse tails were lysed in cell lysis solution (Quiagen) containing 3 U Proteinase K (Fermentas) at 55°C 
overnight under constant agitation. DNA was isolated according to the manufacturer’s protocol and was 
used for genotyping PCR or was stored for short term at 4°C and for long term at -20°C. 
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3.3.5 Generation of mouse embryonic fibroblasts 
L-gp130+ tg mice were bred with C57BL6/N wildtype mice to obtain heterozygous L-gp130+ tg embryos, 
which were dissected at day 13.5 of pregnancy under sterile conditions. Heart, liver and all blood filled 
organs were removed. The embryos were washed in PBS to get rid of all blood. Afterwards the head was 
cut for further digestion and DNA isolation for genotyping PCR. Subsequently, the embryos were 
transferred in to 3 cm dish, cut in very small pieces with a fresh scalpel and incubated with 2 ml 
trypsin-EDTA for 15 min at 37°C. The tissue was shaken gently and resuspended with a shortened pipette 
tip to avoid cell damage. The dissolved tissue was transferred into a 15 ml tube and mixed with 10 ml 
warm DMEM medium containing 10% FCS and 1% Pen-Strep. The cells were pelleted (5 min, 1,000 x g) 
and the supernatant was discarded. Afterwards the cells were resuspended in fresh DMEM medium 
containing 20% FCS and 1% Pen-Strep and were seeded in 10 cm dish. MEF cells were split 1:5 once or 
twice a week and transfected with a vector containing the SV (simian virus) 40 large T antigen using 
Turbofect™ (Fermentas) to achieve immortalization, which was followed by selection with the antibiotic 
G418. 
3.3.6 Plasma preparation of whole mouse blood 
Whole mouse blood was obtained from either tail vein or heart puncture. Tubes coated with 
Lithium-Heparin (Sarstedt) were used to prevent coagulation. The plasma was obtained by centrifugation 
at 10,000 x g for 5 min at 4°C and stored at -20°C.  
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4 RESULTS 
4.1 Point mutations of gp130 
As shown in the crystal structure of the hexameric complex (IL-6/sIL-6R/gp130)2, the domains D1 to D3 
of gp130 are crucial for the recognition of the IL-6/sIL-6R complex (5, 108). One gp130 molecule 
contacts one IL-6/sIL-6R complex engaging its domains D2 and D3 (Fig. 4.1 A). Furthermore, a second 
gp130 molecule binds the IL-6/sIL-6R/gp130 complex via its domain D1 and is indispensable for the 
activation of gp130. Pflanz et al. could show that mutants of gp130 lacking domain D1 revealed impaired 
IL-6 induced signal transduction. Furthermore it has been shown that interference with the residues F191, 
located in domain D2 and V252, located in domain D3 resulted in inhibition of IL-6/IL-6R induced 
signaling, highlighting the importance of the domains D2 and D3 (16, 107). Recently, Rebouissou et al. 
identified gain-of-function mutations of gp130, which showed ligand independent constitutive activation. 
These deletion mutations cluster around the EF loop of domain D2, which represents one IL-6 contact 
site (Tab. 1-2) (130). We speculated that conformational changes of this particular IL-6 binding site 
triggers gp130 activation. We used a rational structure-based mutagenesis approach to interfere with EF 
loop flexibility in domain D2, as well as with the hydrophobic interactions between domains D2 and D3. 
4.1.1 Structural analysis of activating gp130 point mutants 
We analyzed the published crystal structure of gp130 and hypothesized that some amino acid residues 
might be crucial for the proper positioning of the EF loop (Fig. 4.1 B). The cysteine in position 172 
(C172) preceding the EF loop, forms a disulfide bridge to the cysteine in position 182 (C182) and 
therefore stabilizes the EF loop (Fig. 4.1 E). Further, aspartate in position 215 (D215) seems to be a 
crucial residue, since it was found to be deleted in human liver adenoma and led to ligand independent 
activation of gp130 (130). As seen in the crystal structure D215 forms an ionic interaction to the backbone 
amide of F191 in the EF loop and therefore might affect its proper positioning, too (Fig. 4.1 D). 
Therefore, we performed mutagenesis studies to analyze the role of these crucial residues for ligand 
independent activation. The cysteine in position 172 was replaced by serine (C172S), whereas aspartate in 
position 215 was replaced by the small amino acid glycine (D215G) (Tab. 4-1). Moreover, many 
hydrophobic residues cluster around the interface of domain D2 and domain D3. The residues valine in 
position 189 (V189) and tyrosine in position 190 (Y190) of domain D2 as well as valine in position 252 
(V252) of domain D3 are found in close proximity and might influence the hydrophobic connectivity 
between the domains D2 and D3 of gp130 (Fig. 4.1 C). The D3 BC loop containing V252 has been 
shown to be the only flexible region of domain D3 in a solution NMR structure (131). Horsten et al. could 
show a reduced binding of the IL-6/sIL-6R complex to the mutant gp130 V252D (107). In order to find 
out, if these residues and disruption of the hydrophobic core is involved in gp130 activation we replaced 
V189, Y190 and V252 by glycine (Tab. 4-1). 
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Figure 4.1: Activating gp130 deletion mutations cluster on the IL-6 contact site of gp130. (A) 
Crystal structure of the domains D2 and D3 bound to IL-6. (B) Domains D2 and D3 of gp130 without 
IL-6. The EF loop of domain D2 is formed by 2 β-strains (yellow). (C) The interconnecting 
hydrophobic interface of domain D2 (EF loop) and domain D3 (BC loop) including the residues V189, 
Y190 (Tyr-190), F191 (Phe-191), V252 (Val-252) and I253 (Ile-253). (D) The ionic interaction of D215 
(Asp-215) to the EF-loop containing I193 (Ile-193) and F191 (Phe-191). (E) The disulfide bridge 
formed by C172 (Cys-172) and C182 (Cys-182) stabilizing the EF-loop (Schuett et al. submitted). 
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Table 4-1: Crucial residues in gp130 wildtype and their substitutions by mutagenesis PCR. 
mutagenesis function in gp130 wt 
C172S Disulfide bond with C182, stabilization of the EF loop in D2 
V189G Interconnecting hydrophobic area, in the IL-6 contact loop (T183-I193) 
Y190G Interconnecting hydrophobic area, in the IL-6 contact loop (T183-I193) 
D215G Ionic interaction to the backbone of the EF loop in D2 (F191) 
V252G Interconnecting hydrophobic area, in the BC loop of D3 
4.1.2 Biochemical analysis of activating gp130 point mutations 
The gp130 point mutations were generated by mutagenesis PCR. In order to analyze the expression of the 
generated mutants, we transfected HepG2 cells with expression constructs of C-terminal eYFP-tagged 
gp130 variants. Analysis was done by fluorescent microscopy. All mutants were expressed, shown by 
green fluorescence (Fig. 4.2). 
 
Figure 4.2: Microscopic analysis of HepG2 cells transfected with the expression constructs of 
eYFP-tagged gp130 variants. HepG2 cells were transfected with (A) gp130 wt, (B) gp130 V189G, 
(C) gp130 D215G and (D) gp130 V252G. 24 h post transfection cells were analyzed by fluorescence 
microscopy.  
To analyze the activating potential of the generated gp130 mutants HEK 293T cells were transfected with 
the expression constructs of eYFP-tagged gp130 variants, starved over night and lysed. Cells transfected 
with gp130 wt were stimulated with Hyper-IL-6 (HIL-6) to achieve a positive control. STAT3 
phosphorylation was analyzed by SDS-PAGE and subsequent Western blot analysis. Cells expressing the 
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point mutants gp130 C172S, D215G and V252G showed phosphorylation of STAT3 in an autonomous, 
ligand independent manner, whereas the point mutants gp130 V189G and Y190G did not promote any 
autonomous phosphorylation of STAT3 (Fig. 4.3). Differences in ERK phosphorylation were barely 
detectable (data not shown). All gp130 variants were equally expressed, as detected in Western blot 
analysis of cell lysates using anti-GFP antibody. 
  
Figure 4.3: Analysis of STAT3 phosphorylation in cells expressing eYFP-tagged gp130 
variants. HEK 293T cells were transfected with eYFP-tagged gp130 mutants. 24 h post transfection, 
cells were starved for 4 h in serum free medium (SFM). HEK 293T cells transfected with gp130 wt 
were stimulated for 10 min with Hyper-IL-6 (10 ng/ml) and served as positive control . Cell lysates 
were analyzed for phosphorylated STAT3 (P-STAT3), STAT3 and GFP by Western blot analysis. The 
anti-GFP antibody recognizes the YFP-tag. n.t.: non transfected  
Furthermore, receptor phosphorylation of gp130 was analyzed in lysates of transfected cells by 
immunoprecipitation of the eYFP-tagged gp130 variants using either an anti-GFP or an anti-P-Tyr 
antibody. Following immunoprecipitation with an anti-GFP antibody, phosphorylation of the gp130 
mutants C172S, D215G and V252G was observed by Western blot analyis using a specific anti-P-Tyr 
antibody. Gp130 wt and the gp130 variants V189G and Y190G showed receptor phosphorylation to a 
lower extent (Fig. 4.4). Vice versa, precipitation of phosphorylated tyrosine residues using an anti-P-Tyr 
antibody and subsequent Western blot analysis with an anti-GFP antibody showed the same result. 
Gp130 wt did not show autonomous activity, whereas the selected point mutants gp130 C172S, D215G 
and V252G displayed as ligand independent activation. 
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Figure 4.4: Immunoprecipitation of eYFP-tagged gp130 variants and analysis of tyrosine 
phosphorylation. HEK 293T cells were transfected with eYFP-tagged gp130 mutants. 24 h post 
transfection, cells were starved for 4 h in SFM. Cell lysates were analyzed by immunoprecipitation 
using either an anti-GFP or an anti-P-Tyr antibody, followed by SDS-PAGE and Western blot analysis 
for phosphorylated tyrosine (P-Tyr) or GFP, respectively and gp130. The upper band represents the 
complex glycosylated form and the lower band the high-mannose form of gp130. The anti-GFP 
antibody is crossreactive for the YFP-tag. 
To confirm these data, we performed a STAT3 reporter assay in the human hepatoma cell line HepG2. In 
this assay the expression of firefly luciferase is under control of a STAT3 responsive promoter 
(SIEM-Luc). Renilla luciferase (TK-RL) was used as transfection control. Transfected HepG2 cells were 
starved overnight and luciferase expression was measured in cell lysates 24 h post transfection. The ratio 
between firefly and renilla luciferase was calculated and given as fold induction, with non stimulated 
gp130 wt set to 1. Cells transfected with gp130 wt were stimulated for 4 h with Hyper-IL-6. Cells 
expressing the gp130 mutants C172S, D215G and V252G showed increased firefly luciferase activity 
(Fig. 4.5 A). Hyper-IL-6 treatment of cells expressing gp130 wt led to a 4-fold induction of luciferase 
activity, whereas the point mutants gp130 C172S and V252G showed 5-fold and gp130 D215G 10-fold 
induction compared to non-stimulated gp130 wt. Cells expressing the point mutants gp130 V189G and 
Y190G showed no induction of firefly luciferase, which correlates with the absence of STAT3 
phosphorylation in HEK 293T cells. All gp130 variants showed equal expression pattern in a specific 
anti-GFP Western blot (Fig. 4.5 B). 
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Figure 4.5: STAT3 reporter assay of gp130 point mutants.  HepG2 cells were transiently 
co-transfected with a STAT3 responsive promoter construct , which express firefly luciferase (SIEM-
Luc), renilla luciferase (TK-RL) and eYFP-tagged gp130 mutants. Cells were starved over night in 
SFM and cells expressing gp130 wt were stimulated for 4 h with Hyper-IL-6 (HIL-6, 10 ng/ml), serving 
as positive control (A) Luciferase activity was detected by using the Dual-Glo
®
 assay (Promega). The 
fold induction was given with non-stimulated cells expressing gp130 wt set to 1. (B) Cell lysates were 
analyzed for the expression of eYFP-tagged gp130 mutants by Western blot analysis using an 
anti-GFP antibody. The upper band represents the complex glycosylated form and the lower band the 
high-mannose form of gp130. The anti-GFP antibody is crossreactive for the YFP-tag. 
In order to analyse whether the gp130 variants can drive STAT3 dependent proliferation, Ba/F3-gp130 
cells were stably transduced with C-terminal myc-tagged gp130 point mutants. Parental Ba/F3 cells do not 
express endogenous gp130 and exclusively proliferate in the presence of mIL-3, whereas Ba/F3-gp130 
cells express gp130 and therefore respond to Hyper-IL-6. All transduced Ba/F3-gp130 cells expressing 
the myc-tagged gp130 mutants displayed comparable proliferation in the presence of Hyper-IL-6. Cells 
expressing gp130 wt did not show any cytokine independent proliferation, whereas cells expressing the 
gp130 mutants C172S, D215G and V252G were capable to proliferate without any cytokine (Fig. 4.6). 
The fold induction of their proliferation was calculated with non-stimulated gp130 wt set to 1. Cells 
expressing the mutants gp130 C172S and D215G showed a 3-fold induction of proliferation compared to 
non-stimulated Ba/F3-gp130 cells expressing gp130 wt. Furthermore, cells expressing the mutant gp130 
V252G showed a 5-fold induction of cytokine independent proliferation. As expected, the mutations 
V189G and Y190G in gp130 were not sufficient to drive a cytokine independent proliferation. 
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Figure 4.6: Proliferation of Ba/F3-gp130 cells expressing myc-tagged gp130 variants. Cells 
were stably transduced with myc-tagged gp130 wt, and the gp130 mutants C172S, V189G, Y190G, 
D215G and V252G. 5x10
3
 cells7well were seeded in a 96-well plate and proliferation was analyzed 
72 h later using a MTT assay. Cells grew with or without Hyper-IL-6 (10 ng/ml). 
To determine the surface expression, parental Ba/F3 cells were transduced with expression constructs for 
myc-tagged gp130 mutants and analyzed via flow cytometry. Cells were stained using the anti-gp130 
antibody B-P4. Ba/F3-gp130 cells served as an internal positive control (data not shown). All gp130 
variants were present at the cell surface of Ba/F3 cells (Fig. 4.7). 
 
Figure 4.7: Surface expression of the myc-tagged gp130 variants on Ba/F3 cells measured by 
flow cytometry. Stably transduced Ba/F3 cells were analyzed for the surface expression of 
myc-tagged gp130 mutants. 1x10
6
 cells were stained with B-P4 (mouse-anti-gp130) antibody as 
primary and anti-mouse-DyLight 649 as secondary antibody. Light grey: parental Ba/F3 cells. Dark 
grey: Ba/F3 cells stably transduced with the myc-tagged gp130 variants. 
 
 
The proliferation of Ba/F3-gp130 cells was in correlation with STAT3 phosphorylation (Fig. 4.8). To 
analyze the cytokine independent activation of Ba/F3-gp130 cells expressing the myc-tagged gp130 
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mutants, cells were starved in serum free medium. The mutations C172S, D215G and V252G led to a 
cytokine independent phosphorylation of STAT3 (Fig. 4.8 B). In contrast, Ba/F3-gp130 cells transduced 
with myc-tagged gp130 wt, V189G and Y190G showed no phosphorylation of STAT3. Stimulation with 
Hyper-IL-6 or the expression of a constitutive active variant, namely gp130 ΔYY, led to the activation and 
a robust phosphorylation of STAT3 (Fig. 4.8 A, B). Expression of the myc-tagged gp130 variants was 
verified using an anti-gp130 antibody. Due to the low expression levels of endogenous gp130 no 
interference was detectable.  
 
Figure 4.8: Analysis of STAT3 phosphorylation in Ba/F3-gp130 cells expressing myc-tagged 
gp130 variants. Ba/F3-gp130 cells were stably transduced and selected with puromycin. 5x10
6
 cells 
were seeded in a 6-well plate and starved for 4 h in SFM. Ba/F3-gp130 cells transduced with 
myc-tagged gp130 wt were stimulated for 10 min with Hyper-IL-6 (HIL-6, 10 ng/ml), which served as 
positive control. Cell lysates were analyzed for phosphorylated (P-) STAT3, STAT3 and gp130 by 
Western blot. (A) Western blot analysis of non-transduced (n.t.) Ba/F3-gp130 cells and HIL-6 
stimulated and non-stimulated Ba/F3-gp130 cells expressing myc-tagged gp130 wt. (B) Western blot 
analysis of Ba/F3-gp130 cells stably transduced with myc-tagged gp130 wt and the myc-tagged 
gp130 mutants C172S, V189G, Y190G, D215G and V252G. 
To exclude an unspecific proliferative effect of the transduced Ba/F3-gp130 cells, they were treated with 
the pan JAK inhibitor Pyridone 6 (P6). The cytokine independent proliferation of Ba/F3-gp130 cells 
expressing myc-tagged gp130 C172S, D215G and V252G could be inhibited with P6, indicating their 
dependence on Janus kinases (Fig. 4.9).  
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Figure 4.9: Inhibition of gp130 dependent proliferation by the JAK inhibitor Pyridone 6  (P6). 
5x10
3
 cells/well were seeded in a 96-well plate and grew with or without Hyper-IL-6 (HIL-6, 10 ng/ml). 
Stably transduced Ba/F3-gp130 cells expressing myc-tagged gp130 wt, C172S, V189G, Y190G, 
D215G and V252G were treated with 500 nM of P6 as well as HIL6 and proliferation was analyzed 
72 h later using a MTT assay.  
Recently, it has been shown that the antibody B-P4, which binds to an epitope at domain D4 of gp130, 
can inhibit the proliferation of Ba/F3-gp130 cells expressing the constitutive active variant 
myc-gp130 ΔYY (132, 133). The anti-gp130 antibody B-P4 has been described to specifically inhibit IL-11 
and, depending on the cells investigated, IL-6 responses (134–136). To examine if the antibody B-P4 is 
capable to inhibit the proliferation of Ba/F3-gp130 cells expressing the myc-tagged gp130 mutants, we 
analyzed the proliferation of these cells in the presence of B-P4. The antibody B-P4 was able to reduce, 
but could not completely abolish the proliferation of Hyper-IL-6 treated cells, as shown by Sommer et al.. 
Proliferation of cells expressing the point mutants gp130 C172S and D215G was low in the absence of the 
cytokine, compared to cells expressing the mutant gp130 V252G. However, the activity of all of them was 
reduced due to the B-P4 treatment (Fig. 4.10). Highly proliferative cells, expressing the mutants gp130 
V252G or gp130 ΔYY responded best to the inhibitory potential of B-P4. Their proliferation was reduced 
to 80% and 50%, respectively. 
 
Figure 4.10: Proliferation of Ba/F3-gp130 cells expressing myc-gp130 variants is reduced by 
the anti-gp130 antibody B-P4. 5x10
3
 cells/well were seeded in a 96-well plate and grew with or 
without Hyper-IL-6 (HIL-6, 10 ng/ml). Stable transduced Ba/F3-gp130 cells were treated with  1 µg/ml 
of the anti-gp130 antibody B-P4 and proliferation was analyzed 72 h later using a MTT assay. n.t.: 
non transduced. 
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To exclude unspecific side effects of this antibody a different anti-gp130 antibody, which binds to an 
epitope at the C-terminus of gp130 (C-20) was used to examine the proliferation of transduced Ba/F3-
gp130 cells. Proliferation of cells expressing myc-tagged gp130 wt as well as myc-tagged gp130 mutants 
was not affected by this antibody, indicating a specific blocking effect by the anti-gp130 antibody B-P4 
(Fig. 4.11). 
 
Figure 4.11: Proliferation of Ba/F3-gp130 cells expressing myc-tagged gp130 variants is 
reduced by the anti-gp130 antibody C-20. 5x10
3
 cells/well were seeded in a 96-well plate and grew 
with or without Hyper-IL-6 (HIL-6, 10 ng/ml). Stable transduced Ba/F3-gp130 cells were treated with 
1 µg/ml of the anti-gp130 antibody C-20 and proliferation was analyzed 72 h later using a MTT assay. 
n.t.: non transduced. n.t.: non transduced. 
The observations made in Ba/F3-gp130 cells confirm the results obtained from experiments with 
transfected HepG2 and HEK 293T cells. In each experimental setting, the expression of the mutants 
gp130 C172S, D215G and V252G resulted in a cytokine independent activation. This was shown by 
detection of phosphorylated STAT3 in lysates of transfected HEK 293T cells and stably transduced 
Ba/F3-gp130 cells by Western blot analysis. In addition, transfection of the gp130 mutants in HepG2 cells 
led to an activation of a STAT3 reporter. In this context, we furthermore observed an IL-6 independent 
proliferation of Ba/F3-gp130 cells, stably transduced with the mutants gp130 C172S, D215G and V252G.  
4.1.3 Mutations in the constitutive active deletion mutant gp130 ΔYY 
The active deletion mutant gp130 delY186–Y190 (ΔYY) was found in human liver adenoma (Fig. 4.12 A) 
(121). We took advantage of a previously generated eYFP-fusion of the gp130 ΔYY mutant, which 
showed cytokine independent activity in vitro (133). In order to test the impact of the described amino acid 
residues C172, D215 and V252 on the constitutive activation of the gp130 ΔYY mutant, we generated the 
same amino acid substitutions as in wildtype. Additionally, previous work in our laboratory has shown that 
deletion of the first N-terminal domain (ΔD1) of the gp130 ΔYY mutant completely abrogates the 
downstream signaling in HEK 293T cells and Ba/F3 cells (133). The gp130 crystal structure (PDB code: 
1P9M) revealed that the first five N-terminal residues of domain D1 are implicated in IL-6 binding 
(Fig. 4.12 B). We hypothesized that domain D1, including the N-terminal residues E1 to P5, contacts the 
neighboring gp130 and is implicated in activation of gp130 ΔYY. Therefore, we deleted the first five 
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N-terminal amino acids (ΔN1-5) and analyzed the impact of the deletion on the activation of the gp130 
ΔYY mutant. 
 
Figure 4.12: Crystal structure of gp130 wt depicting the deletion mutants ΔYY and ΔN1-5. (A) 
Contact area of IL-6 to domain D2 of gp130, where the residues Y186 to Y190 are deleted in the 
mutant gp130 ΔYY (marked in red). (B) Top view of the hexameric assembly of (gp130 
D1-D3/IL-6/sIL-6R)2 with zoom into the N-terminal portion (red) of domain D1 of gp130 and its 
contact side to IL-6 (green). The N-terminal tail (N1-5) of domain D1 intercalates into a groove of 
IL-6. 
 
Figure 4.13: Microscopic analysis of HepG2 cells transfected with the expression constructs of 
eYFP-tagged gp130 ΔYY and ΔYYΔN1-5. The mutants (A) gp130 ΔYY and (B) gp130 ΔYYΔN1-5 
were expressed in HepG2 cells. 24 h post transfection cells were analyzed by fluorescence 
microscopy.  
EYFP-tagged constructs of the gp130 ΔYY variants were expressed in HepG2 cells as shown by 
fluorescence microscopy (Fig. 4.13). The analysis of cytokine independent activation of STAT3 in HEK 
293T cells showed no difference between the mutants gp130 ΔYY, gp130 ΔYY D215G and gp130 ΔYY 
V252G. Cells expressing the mutant gp130 ΔYY C172S showed slightly reduced phosphorylation of 
STAT3. As expected, cells expressing the mutant gp130 ΔYYΔD1 showed impaired STAT3 
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phosphorylation, whereas the mutant gp130 ΔYYΔN1-5 was still active, but showed reduced STAT3 
phosphorylation as compared to the gp130 ΔYY mutant. Equal expression of all gp130 variants were 
detected in Western blot analysis of cell lysates using anti-GFP antibody (Fig. 4.14). 
 
Figure 4.14: Analysis of STAT3 phosphorylation variants in cells expressing eYFP-tagged 
gp130 variants. HEK 293T cells were transfected with eYFP-tagged gp130 ΔYY mutants. 24 h post 
transfection, cells were starved for 4 h in SFM. HEK 293T cells transfected with gp130 wt were 
stimulated 10 min with Hyper-IL-6 (10 ng/ml) as a positive control. Cell lysates were analyzed for 
phosphorylation of STAT3 (P-STAT3), STAT3 and GFP in Western blot. Anti-GFP antibody is 
crossreactive for the YFP-tag. n.t.: non transfected. 
In order to analyze STAT3 activation in a hepatic cell background, HepG2 cells were co-transfected with 
a STAT3 responsive promoter construct (SIEM-Luc) expressing firefly luciferase, a vector encoding 
renilla luciferase along with the indicated expression constructs for the gp130 ΔYY mutants. The ratio 
between firefly and renilla luciferase was calculated and the fold induction was given with non-stimulated 
gp130 wt set to 1. Cells transfected with gp130 wt were stimulated for 4 h with Hyper-IL-6. Cells 
expressing the mutant gp130 ΔYY showed 17-fold induction, which is twofold more than Hyper-IL-6 
stimulated cells expressing gp130 wt. All gp130 ΔYY point mutations led to the activation of the STAT3 
responsive promoter (Fig. 4.15 A). Interestingly, cells expressing the point mutants gp130 ΔYY D215G 
and V252G had a 1.5-fold elevated activation of STAT3 compared to cells expressing the mutants gp130 
ΔYY. Surprisingly, the mutant gp130 ΔYY C172S displayed as well cytokine independent activation but 
showed one-third reduced activation compared to the gp130 ΔYY mutant. The deletion of domain D1 
(ΔD1) in the gp130 deletion mutant ΔYY led to impaired luciferase activity due to no significant activation 
of the STAT3 responsive promoter. Deletion of the N-terminal portion (ΔN1-5) of the gp130 ΔYY 
mutant led to 10-fold induction of luciferase activity, which was reduced to 50% compared the mutant 
gp130 ΔYY. Equal expression of the gp130 variants was confirmed by anti-GFP Western blot 
(Fig. 4.15 B).  
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Figure 4.15: STAT3 reporter assay of gp130 ΔYY variants. HepG2 cells were transiently 
co-transfected with STAT3 responsive promoter construct expressing firefly luciferase (SIEM-Luc), 
renilla luciferase (TK-RL) and eYFP-tagged gp130 ΔYY mutants. Cells were starved over night in 
SFM and cells expressing gp130 wt were stimulated 4 h with Hyper-IL-6 (HIL-6, 10 ng/ml). (A) 
Luciferase activity was detected using the Dual -Glo
®
 assay (Promega). (B) Cell lysates were 
analyzed for the expression of eYFP-tagged gp130 mutants by Western blot, using anti-GFP 
antibody. The upper band represents the complex glycosylated form and the lower band the high -
mannose form of gp130.  The anti-GFP antibody is crossreactive for the YFP-tag. 
In order to find out if the gp130 ΔYY variants can drive STAT3 dependent proliferation, myc-tagged 
mutants were stably transduced into Ba/F3-gp130, as described for the gp130 wt variants. Cells expressing 
myc-tagged gp130 ΔYY displayed Hyper-IL-6 independent proliferation, which resulted in a 9-fold 
induction of proliferation compared to non stimulated Ba/F3-gp130 cells (Fig. 4.16). The deletion of 
domain D1 in the mutant gp130 ΔYYΔD1 led to an impaired proliferation in cytokine free medium, 
whereas the mutant gp130 ΔYYΔN1-5 showed cytokine independent proliferation, which was reduced by 
50% compared to cells expressing the mutant gp130 ΔYY. This result stands in line with the results from 
the STAT3 reporter assay, indicating that the mutant gp130 ΔYYΔN1-5 is less active than the mutant 
gp130 ΔYY. 
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Figure 4.16: Proliferation of Ba/F3-gp130 cells expressing myc-tagged gp130 ΔYY variants. 
5x10
3
 cells/well were seeded in a 96-well plate, grew with or without 10 ng/ml of Hyper -IL-6 (HIL-6) 
and proliferation was analyzed 72 h later using a MTT assay. Cell were stably transduced with myc-
tagged gp130 ΔYY, ΔYYΔD1 and ΔYYΔN1-5 selected with puromycin. n.t.: non transfected. 
Furthermore, proliferation assays were conducted with Ba/F3-gp130 cells expressing the myc-tagged 
gp130 mutants ΔYY C172S, D215G and V252G. The latter mutants drove cytokine independent 
proliferation, whereas cells expressing the mutant gp130 ΔYY C172S showed an impaired proliferative 
potential. To exclude an unspecific proliferation of the stably transduced Ba/F3-gp130 cells, they were 
treated with the pan JAK inhibitor Pyridone 6 (P6). The cytokine independent proliferation of cells 
expressing the mutants gp130 ΔYY C172S, D215G, V252G and ΔN1-5 were inhibited with P6, indicating 
their dependence on Janus kinases (Fig. 4.17).  
 
Figure 4.17: Inhibition of gp130 ΔYY dependent proliferation with the JAK inhibitor Pyridone 6 
(P6). 5x10
3
 cells/ well were seeded in a 96-well plate and grew with or without Hyper-IL-6 (10 ng/ml). 
Stably transduced Ba/F3-gp130 cells were treated with 500 nM of P6 and proliferation was analyzed 
72 h later using a MTT assay. 
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In addition, analysis of STAT3 phosphorylation in Ba/F3-gp130 cells transduced with the myc-tagged 
gp130 mutants showed activation of all gp130 ΔYY mutants except for the mutant gp130 ΔYYΔD1 
(Fig. 4.18 A, B). As seen in the STAT3 reporter assay and in the proliferation study, cells expressing the 
mutants gp130 ΔYY C172S and gp130 ΔYYΔN1-5 showed reduced STAT3 phosphorylation, indicating 
that the mutations interfere with constitutive activation of gp130 ΔYY deletion mutant. The expression of 
the myc-tagged gp130 constructs was confirmed in Western blot analysis using an anti-gp130 antibody. 
Due to the low expression levels of endogenous gp130 no interference was detectable (Fig. 4.18).  
 
Figure 4.18: Analysis of STAT3 phosphorylation in Ba/F3-gp130 cells expressing myc-tagged 
gp130 variants. Ba/F3-gp130 cells were stably transduced and selected with puromycin. 5x10
6
 cells 
were seeded in a 6-well plate and starved for 4 h in SFM. Ba/F3-gp130 cells expressing myc-tagged 
gp130 wt were stimulated for 10 min with Hyper-IL-6 (HIL-6, 10 ng/ml). Cell lysates were analyzed for 
phosphorylated (P-) STAT3, STAT3 and gp130 (C-20) by Western blot analysis. (A) Western blot 
analysis of Ba/F3-gp130 cells stably transduced with the mutants gp130 ΔYY, ΔYYΔD1 and 
ΔYYΔN1-5. (B) Western blot analysis of Ba/F3-gp130 cells stably transduced with gp130 wt and ΔYY 
mutants. 
Parental Ba/F3 cells were stably transduced with myc-tagged gp130 contructs and analyzed via flow 
cytometry to figure out, if the mutanted gp130 proteins are present at the cell surface. Cells were stained 
using the anti-gp130 antibody B-P4. Expression was compared to parental Ba/F3 cells. Cells stably 
transduced with GFP were used as control. For all gp130 mutants no cell surface staining was detectable. 
Therefore, cells were permeabilized and stained for intracellular gp130 using the antibody B-P4 as well. All 
cells transduced with the expression constructs of the myc-tagged gp130 variants showed detectable 
expression, indicating that the gp130 ΔYY variants were localized intracellularly (Fig. 4.19). These results 
correlate with an impaired maturation of the gp130 ΔYY mutant, which has been recently found in our 
laboratory (data not shown). 
These data imply that the activity of the constitutive active deletion mutant gp130 ∆YY can be reduced. 
We discovered that the mutation C172S as well as the deletion of the N-terminal portion (∆N1-5) 
interferes with the autonomous activity of STAT3 in the mutant gp130 ΔYY. These two mutants showed 
reduced phosphorylation of STAT3 in Western blot analysis of transfected HEK 293T cells. Furthermore, 
expression of gp130 ∆YY C172S and gp130 ∆YY∆N1-5 led to impaired luciferase activity in a STAT3 
reporter assay in HepG2 cells. Retroviral transduction of Ba/F3-gp130 cells with these gp130 ΔYY 
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mutants resulted in a ligand independent but reduced proliferation as well as diminished STAT3 
activation. 
 
Figure 4.19: Flow cytometric analysis of the surface and the intracelluar expression of 
myc-tagged gp130 ΔYY variants. Ba/F3 cells were stably transduced with myc-tagged gp130 ΔYY 
variants. For detection of gp130 expression the mouse-anti-gp130-antibody (B-P4) was used as 
primary and anti-mouse-DyLight 649 as secondary antibody. Light grey: parental Ba/F3 cells . Dark 
grey: Ba/F3 cells stably transduced with myc-tagged gp130 ΔYY variants. 
4.1.4 SOCS3 mediated suppression of STAT3 signaling 
IL-6 induces the expression of SOCS3, which binds to JAK2 and is therefore a potent inhibitor of gp130 
induced STAT3 phosphorylation. Constitutive active variants of gp130 such as the mutant gp130 ∆YY 
lead to the upregulation of SOCS3 (121). Nevertheless, STAT3 activation persists. In order to find out if 
constitutive active gp130 mutants are insensitive to SOCS3 inhibition, we co-expressed a myc-tagged 
SOCS3 construct with the gp130 point mutants C172S, D215G and V252G in HEK 293T cells. 
Overexpression of SOCS3 resulted in a strong reduction of phosphorylated STAT3 in cells expressing the 
constitutive active mutants gp130 C172S, D215G and V252D as well as in cells expressing the mutant 
gp130 ΔYY (Fig. 4.20). An equal expression of all gp130 constructs was confirmed by Western blot 
analysis of the cell lysates using an anti-GFP antibody. 
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Figure 4.20: Inhibition of STAT3 phosphorylation due to SOCS3 overexpression in cells 
expressing the gp130 variants. HEK 293T cells were co-transfected with a myc-tagged SOCS3 
construct and eYFP-tagged gp130 constructs. Cells transfected with gp130 wt were stimulated for 
10 min with Hyper-IL-6 (HIL-6, 10 ng/ml). 24 h post transfection, cell lysates were analyzed for 
phosphorylated (P-) STAT3, STAT3, myc and GFP in Western blot. The anti-GFP antibody is 
crossreactive for the YFP-tag. 
4.1.5 Dimerization studies of gp130 mutants 
Previously, it has been shown by Tenhumberg et al., that gp130 wt exists as preformed but inactive 
homodimer (12). The interaction was analyzed by co-immunoprecipitation and confirmed by FRET 
analysis. They postulated that ligand binding can enhance the dimer formation and is required for signal 
transduction. Rebouissou et al. showed that the gp130 ΔYY mutant can associate with itself and gp130 wt, 
resulting in dimer formation (121). To analyze dimerization of the generated point mutants the expression 
constructs of eYFP- and myc-tagged gp130 variants were co-expressed in HEK 293T cells. Cells were 
starved to analyze phosphorylation of STAT3 and gp130. Cells expressing gp130 wt were non-stimulated. 
The differently tagged proteins were co-immunoprecipitated, either using an anti-myc or an anti-GFP 
antibody. Western blot analysis of precipitated proteins indicated that the expressed mutants displayed a 
constitutive dimerization. Precipitation of eYFP-tagged gp130 variants with anti-GFP antibody resulted in 
the detection of myc-tagged gp130 variants and vice versa. Co-expression of the constitutive active 
eYFP- and myc- tagged mutants gp130 C172S, D215G and V252G resulted in receptor phosphorylation, 
which cannot be seen in gp130 wt (Fig. 4.21 B). These results were confirmed by Western blot analysis of 
cell lysates for phosphorylated STAT3 (Fig. 4.21 A). These data indicate a constitutive dimerization of 
gp130 variants irrespective of their activation status. 
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Figure 4.21: Immunprecipitation and detection of dimer formation of gp130 wt and the gp130 
variants C172S, D215G and V252G. HEK 293T cells were co-transfected with the expression 
constructs of eYFP- and myc-tagged gp130 variants. Cells were starved 24 h post transfection and 
lysed. Cell lysates were used for Western blot analysis and for immunoprecipitation  (IP). (A) Western 
blot analysis of lysates for phosphorylated (P-) STAT3, STAT3, myc and GFP. (B) Co-
immunoprecipitation of cell lysates and detection of phosphorylated tyrosine (P-Tyr), GFP and myc 
using specific antibodies. The anti-GFP antibody is crossreactive for the YFP-tag. 
It has been shown that the deletion of domain D1 in gp130 wt led to unresponsiveness to IL-6/sIL-6R 
stimulation and impaired the constitutive active signaling of the mutant gp130 ΔYY (16, 133). Therefore 
we postulate that domain D1 is potentially implicated in dimerization of gp130. To investigate gp130 
dimerization, eYFP- and myc–tagged mutants gp130 ΔYY, ΔYYΔD1 and ΔYYΔN1-5 were co-expressed 
in HEK 293T cells and were analyzed for receptor phosphorylation under starving conditions. Formation 
of dimers was analyzed by precipitation of eYFP- and myc-tagged gp130 variants using an anti-GFP or an 
anti-myc antibody as described before. Immunoprecipitates were analyzed by Western blot using an 
antibody against the corresponding tag. Homodimer formation between the mutants gp130 ΔYY, ΔD1 
and ΔN1-5 was detectable, concluding that the mutant gp130 ΔYY can dimerize irrespective of domain 
D1 and of its activation status (Fig. 4.22 A). Moreover, the mutant gp130 ΔYY was able to form 
heterodimers with the mutant gp130 ΔYYΔD1. The mutant gp130 ΔYYΔN1-5 as well as the mutant 
gp130 ΔYYΔD1 can be co-precipitated with the mutant gp130 ΔYYΔN1-5 (Fig. 4.22 B). 
To sum up, gp130 ΔYY variants dimerize, when expressed in HEK 293T cells, irrespective of their 
activation status. 
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Figure 4.22: Immunoprecipitation and detection of dimer formation of the variants gp130 ΔYY, 
ΔYYΔD1 and ΔYYΔN1-5. HEK 293T cells were co-transfected with the expression constructs of 
eYFP- and myc tagged gp130 variants. Cells were starved and lysed 24 h post transfection. Cell 
lysates were analyzed using an anti-myc or an anti-GFP antibody for immunoprecipitiation. 
Precipitated proteins were analyzed for phosphorylated tyrosine residues in gp130 and for the 
corresponding tag in Western blot.  Size of eYFP-tagged proteins is increased by 26 kDa. The 
anti-GFP antibody is crossreactive for the YFP-tag. (A) Homodimers of eYFP- and myc-tagged gp130 
ΔYY, ΔYYΔD1 and ΔYYΔN1-5 mutants. (B) Heterodimers of eYFP- and myc-tagged gp130 ΔYY, 
ΔYYΔD1 and ΔYYΔN1-5 mutants. First named construct is eYFP-tagged and second named is myc-
tagged. 
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4.2 Leucin-gp130: a ligand independent constitutive active gp130 variant  
Previously an artificial constitutive active version of gp130 has been generated in our laboratory (see 
introduction point 1.8) (123). Replacing the extracellular domain with the leucine-zipper motif of c-Jun, 
which is stabilized by a cysteine bridge, led to the activation of an IL-6 like mediated signaling. This 
construct was named Leucin-gp130 (L-gp130). Expression of L-gp130 in HepG2 cells resulted in cytokine 
independent activation and phosphorylation of STAT3 and to ligand independent proliferation of stably 
transduced Ba/F3-gp130 cells. L-gp130 was able to suppress spontaneous differentiation of murine 
embryonic stem cells in the absence of LIF. In order to analyze physiological consequences of constitutive 
gp130 activation, we generated transgenic mice expressing a doxycycline inducible construct of L-gp130. 
4.2.1 Inducible expression of L-gp130 via the Tet-system 
Permanent activation of gp130 signaling is supposed to be cancerogenic due to constitutive active STAT3 
(see introduction point 1.4). For this reason, the expression of L-gp130 was temporally restricted by using 
the inducible tetracycline sensitive (Tet-) system. The transgene L-gp130 as well as the reporter gene firefly 
luciferase were expressed under control of a tetracyline responsive promoter element (TRE). The Kozak 
sequence for L-gp130 was optimized to achieve optimal expression. Activation of TRE can be achieved 
via either the tetracycline transactivator protein (tTA) or the reverse tetracycline transactivator protein 
(rtTA) in dependence of doxycycline (Dox). These transactivator proteins were expressed by Tet-vectors. 
A selective expression of tTA or rtTA can be achieved by the use of a tissue specific promoter. (see 
introduction point 1.10 and Fig. 4.23 for further details) 
 
Figure 4.23: Used Tet-vectors in this study. The vector pBI5 contains a tetracycline responsive 
promoter element (TRE) fused to two differgently orientated hCMV minimal promoters. Tet-off vectors 
express the tetracycline transactivator protein (tTA) and Tet-on vectors express the reverse 
tetracycline transactivator protein (rtTA) under control of a specific promoter, respectively.  A liver 
specific promoter (Lap) and a general promoter (hCMV) were used to induce the expression of tTA 
and rtTA. 
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4.2.2 Expression of pBI5-L-gp130  
To test the inducible expression via the transactivator tTA, the human hepatoma cell line HepG2 was 
transfected with equal amounts of pBI5-GFP, expressing GFP under control of a tetracyline responsive 
promoter element (TRE) and the Tet-off vector pTan-Pur, which expresses the tetracycline transactivator 
(tTA). Transfected cells were analyzed by fluorescence microscopy using pcDNA3.1-eGFP transfected 
cells as control. Single transfection with pBI5-GFP did not drive the expression of the transgene GFP, 
which was observed by co-ransfection with the Tet-off vector pTan-Pur. The GFP expression of cells 
transfected with pBI5-GFP and pTan-Pur was comparable to cells transfected with pcDNA3.1-eGFP 
(Fig. 4.24). 
 
Figure 4.24: Analysis of inducible GFP expression using the Tet-off sytsem. Fluorescence 
microscopy images of HepG2 cells transfected with pcDNA3.1 -eGFP and pBI5-GFP +/- the Tet-off 
vector pTan-Pur. 
Furthermore, HepG2 cells were co-transfected with pBI5-L-gp130, which express L-gp130 as well as 
firefly luciferase and the Tet-off vector pTan-Pur. Luciferase levels were determined via luciferase assay. 
The co-expression resulted in high levels of L-gp130 already 24 h post transfection, analyzed in Western 
blot using anti-gp130 antibody (Fig. 4.25 A). Single transfection of HepG2 cells with the construct 
pBI5-L-gp130 did not lead to transgene expression. The expression of L-gp130 was completely inhibited 
by the addition of doxycycline (Dox). Analysis of the luciferase activity of transfected cells by luciferase 
assay confirmed this data. The dose response curve revealed that 1 µg/ml Dox was sufficient to suppress 
luciferase activity (Fig. 4.25 B). In time course experiments we identified the earliest time point of 
doxycycline dependent inhibition of luciferase expression. As shown in Fig. 4.25 C the luciferase activity 
decreased 3 h after Dox was supplemented and reached a minimum level after 6 h. A complete inhibition 
of luciferase activity and L-gp130 expression was achieved after 24 h. This experimental setting was 
chosen for futher experiments. 
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Figure 4.25: Analysis of inducible expression of pBI5-L-gp130. (A) HepG2 cells were transfected 
with pBI5-L-gp130 +/- pTan-Pur and treated with doxycycline (1 µg/ml)  24 h post transfection. Cell 
lysates were analyzed with anti-gp130 antibody (C-20) in Western blot. (B) HepG2 cells were 
transfected with pBI5-L-gp130 +/- pTan-Pur and treated with different concentrations of doxycyc line 
(Dox, 1 - 2 µg/ml, n=1) 24 h post transfection. Cell lysates were analyzed using luciferase assay 
(Promega). (C) Time course of doxycycline dependent inhibition of gene expression. HepG2 cells 
were transfected with pBI5-L-gp130 and pTan-Pur (n=1), 1 µg/ml doxycycline was added 24 h post 
transfection and luciferase activity was analyzed hourly.  RLU: relative light units. 
Different Tet-off and Tet-on vectors expressing tTA or rtTA under control of either a general (hCMV) or 
a liver specific (Lap) promoter were co-transfected with pBI5-L-gp130 in HepG2 cells. Cells were treated 
with doxycycline immediately following transfection and lysed 24 h post transfection. Lysates were 
analyzed for luciferase activity by luciferase assay and for L-gp130 expression by Western blot using an 
anti-gp130 antibody. To analyse the fold induction, cells transfected with pBI5-L-gp130 and without Dox 
treatment were set to 1. Cells expressing pBI5-L-gp130 and hCMV-tTA, showed 40-fold induction of 
luciferase activity in the absence of Dox, which was downregulated to 4-fold induction by the addition of 
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Dox. A similar expression of luciferase was detected in cells expressing pBI5-L-gp130 and Lap-tTA. The 
co-transfection of HepG2 cells with pBI5-L-gp130 and the Tet-on vector hCMV-rtTA led to a significant 
induction of luciferase in the presence of Dox. Doxycycline treatment induced the expression of luciferase 
in cells expressing pBI5-L-gp130 and hCMV-rtTA up to 20-fold compared to non treated cells. Cells 
co-transfected with pBI5-L-gp130 and Lap-rtTA showed twofold higher luciferase activity compared to 
cells expressing rtTA under control of the hCMV promoter. Comparing both Tet-on vectors, the liver 
specific Lap promoter caused a stronger expression of luciferase compared to the hCMV promoter, which 
can be explained by the usage of a hepatocellular cell line. These data were confirmed by Western blot 
analysis of L-gp130 expression. Both Tet-systems worked properly, since tTA as well as rtTA were 
sufficient to induce expression of L-gp130 and firefly luciferase (Fig. 4.26). 
 
 
Figure 4.26: Analysis of luciferase activity and L-gp130 expression using different Tet-vectors. 
HepG2 cells were co-transfected with the indicated plasmids and were lysed 24 h after Dox 
treatment. Lysates were analyzed for luciferase activity using luciferase assay (Promega). Cells 
transfected with pBI5-L-gp130 without doxycycline treatment was set to 1. Lysates were analyzed for 
L-gp130 expression in Western blot using anti -gp130 antibody (C-20). 
4.2.3 SOCS3 mediated suppression of L-gp130  
It has been already shown that IL-6 signaling leads to upregulation of SOCS3. This potent inhibitor binds 
to phosphorylated Y759 in the intracellular domain of gp130 and down regulates the signaling of activated 
gp130. We threfore addressed the question, if the constitutive active L-gp130 is sensitive to SOCS3 
mediated suppression. A myc-tagged SOCS3 construct was co-transfected with different L-gp130 
expression contructs in HepG2 cells. The construct p409-L-gp130 as well as the inducible construct of 
pBI5-L-gp130 in combination with pTan-Pur were analyzed. In both cases the expression of L-gp130 led 
to a ligand independent activation and phosphorylation of STAT3. Mock transfected cells were stimulated 
with Hyper-IL-6 as a positive control. Overexpression of SOCS3 diminished L-gp130 mediated STAT3 
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phosphorylation. Interestingly, STAT3 phosphorylation induced by Hyper-IL-6 stimulation of mock 
transfected cells was not inhibited by SOCS3 overexpression (Fig. 4.27).  
 
Figure 4.27: Overexpression of SOCS3 led to inhibition of L-gp130 mediated STAT3 
phosphorylation. HepG2 cells were co-transfected with L-gp130 constructs and myc-tagged SOCS3 
as indicated. Mock transfected cells served as control and were stimulated with Hyper-IL-6 (HIL-6, 
10 ng/ml). Cells were lysed 24 h post transfection and lysates were analyzed for phosphorylated (P-) 
STAT3, STAT3 and myc in Western blot. 
4.2.4 Generation of L-gp130+ transgenic mice 
In parallel to the validation of the Tet-system in vitro, the construct pBI5-L-gp130 was linearized and used 
to generate transgenic mice via pronucleii injection (IBF, Heidelberg). The offspring were analyzed via 
genotyping PCR and Southern blot (Fig. 4.28 B, C). Genomic insertion was determined by specific 
primers for the luciferase gene and for the L-gp130 gene. Primers used for PCR analysis bind to the 
sequence of leucine zipper and the intracellular domain of L-gp130. Primers used to generate a probe for 
Southern blot analysis amplified the full length L-gp130 gene (Fig. 4.28 A). 
Altogether, eleven strains were tested positive for the insertion of the L-gp130 gene as well as for the 
luciferase gene. The transgene was not expressed in the absence of the transactivator and therefore the 
L-gp130+ transgenic (tg) mice developed no visible phenotype. The fertility of some strains was either 
restricted to few generations or the generation size was limited. Finally, five strains (L2, L5, L9, L11 and 
L12) were selected to generate mEF cells and double transgenic (dtg) animals in order to analyze the 
inducible expression of L-gp130.  
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Figure 4.28: Genotyping of L-gp130
+
 tg mice. Tail DNA was analyzed for insertion of the transgene 
firefly luciferase and L-gp130. (A) Primer design and expected PCR product size. (B) Genotyping 
PCR of L-gp130
+
 tg and wildtype (wt) mice. (C) Southern blot analysis of L-gp130
+
 tg and wildtyp (wt) 
mice. Plasmid DNA (10 ng/ 0.1 ng) of pBI5-L-gp130 was used as internal control. 
4.2.5 Generation of L-gp130+ murine embryonic fibroblasts 
In order to analyze the inducible expression of L-gp130 and firefly luciferase ex vivo, we generated murine 
embryonic fibroblasts (mEF cells) from L-gp130+ tg mice. Therefore, heterozygous L-gp130+ tg mice 
were bred with wildtype mice and the embryos were sacrificed at day E13. Resulting mEF cells were either 
negative or positive for L-gp130 insertion revealed by genotyping PCR. MEF cells were generated from 
four L-gp130+ strains (L2, L5, L9 and L11) to analyze differences in genomic integration among these 
strains. Different mEF cell clones (one embryo = one cell clone) of the corresponding L-gp130+ tg mouse 
were tested for their background luciferase activity. In the absence of the transactivator (tTA), no 
luciferase activity was detectable in L-gp130+ mEF cells of L2, L5 and L9. Only L-gp130+ mEF cells of 
L11 showed tTA independent background luciferase activity (Fig. 4.29 A). To activate transgene 
expression, L-gp130+ mEF cells were retrovirally transduced with the transactivator tTA. Stable cell lines 
were generated by puromycin selection. MEF cells expressing L-gp130 and tTA were analyzed for 
luciferase activity via luciferase assay as well as for L-gp130 expression by Western blot using an 
anti-gp130 antibody. L-gp130+/tTA+ mEF cells generated from strain 2 (L2) and 5 (L5) showed a tTA 
dependent induction of luciferase activity as well as an expression of L-gp130 revealed by luciferase assay 
and Western Blot, respectively. L-gp130+/tTA+ mEF cells of L5 showed higher induction of luciferase 
activity compared to L-gp130+/tTA+ mEF cells of L2 (Fig. 4.27 B, C). The luciferase activity detected in 
L-gp130+/tTA+ mEF cells from L5 was diminished by doxycycline (1 µg/ml) highlighting the inducible 
gene expression (Fig. 4.27 D).  
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Figure 4.29: Expression of luciferase and L-gp130
+
 in mEF cells. L-gp130
+
 mEF cells were 
generated from L-gp130
+
 tg mice of L2, L5, L9 and L11. (A) L-gp130
+
 mEF cells were tested for 
background luciferase activity via luciferase assay (Promega). (B) Stably transduced L-gp130
+
/tTA
+
 
mEF cells were analyzed for the expression of luciferase via luciferase assay (Promega). (C) 
Expression of L-gp130 in L-gp130
+
/tTA
+
 mEF cells was analyzed in Western blot using anti-gp130 
antibody (C-20). (D) Analysis of luciferase activity following doxycycline treatment of L-gp130
+
/tTA
+
 
mEF cells of L5 using luciferase assay (Promega). RLU: relative light units. 
4.2.6 Generation of double transgenic mice to induce the expression of L-gp130 
In order to achieve a tissue specific inducible expression of L-gp130 in vivo, transgenic mice were bred 
with different Tet-inducer strains. We used Lap-tTA+ tg mice, expressing the transactivator tTA under the 
control of a liver specific promoter and hCMV-tTA+ tg mice, which display an ubiquitous tTA expression 
(Fig. 4.30). All generated double transgenic (dtg) mice were bred heterozygous for their transgenes. The 
occurance of wt, tg and dtg mice were as expected according to Mendel's laws. We therefore expected 
25% dtg mice. 
 
Figure 4.30: Generation of double transgenic mice.  Mice heterozygous for L-gp130
+
 or tTA
+
 were 
bred to generate Lap-tTA
+
/L-gp130
+
 dtg mice or hCMV-tTA
+
/L-gp130
+
 dtg mice according to Mendel’s 
law. Colors depicted in this scheme did not correlate with the hair color of the mice.  
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To suppress an early L-gp130 expression, breeding pairs were constantly kept on doxycycline 
supplemented nutrition (see methods). Four L-gp130+ tg strains were used to generate double transgenic 
mice (Lap-tTA+/L-gp130+). We tested different conditions to induce transgene activation and analyzed 
the induction by measuring the luciferase activity in the liver. We varied the time point of doxycycline 
withdrawal (age of the mice) as well as the duration of induction (Fig. 4.31, Tab. 4-2). It has been shown 
that doxycycline persists in the body up to one week until it is eliminated via catabolic pathways, before 
causing a full and stable transgene expression (127). 
 
Figure 4.31: Scheme of doxycycline treatment and transgene induction time of double 
transgenic mice. Doxycycline was given in drinking water or food pellets. Either nutrion was not 
supplemented with doxycycline or was withdrawn at different age of the mice (see methods). 
 
Table 4-2: Doxycycline treatment and induction time points of Lap-tTA
+
/L-gp130
+
 dtg mice. 
Dox withdrawal (age of mice) Induction time 
8 weeks 3 weeks 
 6.5 weeks   (Fig. 4.32 B) 
 16 weeks 
3 weeks 1 week 
 10 days       (Fig. 4.32 C) 
 4 weeks      (Fig. 4.32 C) 
 11 weeks 
 14 weeks 
2 weeks 16 weeks 
Day 2 7 weeks 
No Dox treatment 8 weeks 
We analyzed livers of Lap-tTA+/L-gp130+ dtg mice for transgene expression. Both genders were used for 
all analyses. Liver samples were taken to analyze RNA, protein and luciferase expression. At no time point 
the expression of L-gp130 was detectable in the liver lysates of Lap-tTA+/L-gp130+ dtg mice by Western 
blot (data not shown). In accordance, no phosphorylated STAT3 was detectable (data not shown). The 
expression of the transactivator tTA was analyzed by Western blot of liver lysates, using antibodies 
specific for either VP16 or TetR. These antibodies failed to recognize their epitope, even in lysates of 
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cells, which show overexpressing of tTA (data not shown). The livers of Lap-tTA+/L-gp130+ dtg mice 
were tested for luciferase activity as well, due to the bidirectional expression of L-gp130 and firefly 
luciferase. L-gp130+ tg mice were tested and a background luciferase activity was detectable in liver lysates 
of L-gp130+ tg mice of strain 11 (L11) and 12 (L12), similar to what we detected in mEF cells (Fig. 4.32, 
Fig. 4.29 A). However, the level of luciferase was significantly lower comparing to published data. 
 
Figure 4.32: Analysis of luciferase activity in the liver of L-gp130
+
 tg mice. Livers of L-gp130
+
 tg 
mice (L5, L11, L12) were tested for background expression of firefly luciferase using luciferase assay 
(Promega). RLU: relative light units. 
Wildtype mice showed no induction of luciferase expression in all experiments. No significant luciferase 
activity was detected in liver lysates of Lap-tTA+/L-gp130+ dtg mice compared to published data, 
although different parameters for transgene induction were analyzed (Tab. 4.2). Two experiments are 
depicted using Lap-tTA+/L-gp130+ dtg mice of strain 5 (L5) and 12 (L12) (Fig. 4.33 B, C). Nevertheless, a 
slightly increased luciferase expression was detected in Lap-tTA+/L-gp130+ dtg mice compared to 
L-gp130+ tg mice and wildtype mice.  
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Figure 4.33: Analysis of luciferase activity in livers of Lap-tTA
+
/L-gp130
+
 dtg mice. (A) Livers of 
Lap-tTA
+
/ L-gp130
+
 dtg mice (L12) were analyzed 6.5 weeks after Dox withdrawal for luciferase 
expression by luciferase assay (Promega). (B) Livers of Lap-tTA
+
/L-gp130
+
 dtg mice (L5) were 
analyzed 10 days and 1 month after Dox withdrawal for luciferase expression by luciferase assay 
(Promega). RLU: relative light units. 
4.2.7 In vivo imaging of Lap-tTA+/L-gp130+ dtg mice 
To further analyze the transgene expression of Lap-tTA+/L-gp130+ dtg mice, luciferase activity was 
measured in vivo using a CCD camera. Mice were kept on doxycycline supplemented nutrition until the age 
of 8 weeks and analyzed 6.5 weeks later for the induction of luciferase in the liver. L-gp130+ tg mice (L12) 
injected with luciferin showed background luminescence, whereas no luminescene was detectable in 
injected wildtype mice. Double transgenic Lap-tTA+/L-gp130+ mice did not show an increased induction 
of luminescence compared to L-gp130+ tg mice (Fig. 4. 34). The detected bioluminescene was ubiquitous 
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and not restricted to the liver. These results were in line with the analysis of luciferase activity in liver 
lystates of L-gp130+ tg mice and Lap-tTA+/L-gp130+ dtg mice (Fig. 4.33 A). 
 
Figure 4.34: In vivo imaging of Lap-tTA
+
/L-gp130
+
 dtg mice (L12). Following an induction time of 
6.5 weeks mice were injected with 150 µg luciferin/ g bodyweight. After an incubation period, while 
the substrate is converted by luciferase, mice were narcotized by ketamine and xylazine. The 
bioluminescence in living mice was measured with a CCD camera (Berthold NightOWL) and an 
integration time of 2 min. 
Furthermore, liver RNA of Lap-tTA+/L-gp130+ dtg mice were tested for the expression of tTA and 
L-gp130. In our hands, it was impossible to detect the transcripts neither for tTA nor for L-gp130 using 
RT-PCR (data not shown).  
4.2.8 Acute phase response of Lap-tTA+/L-gp130+ dtg mice 
It is known that IL-6 mediated STAT3 signaling induces acute phase response in the liver resulting in an 
upregulation of acute phase proteins, such as serum amyloid A (SAA). The activation of a constitutive 
active gp130 variant in the liver may cause the induction of SAA as well. Since the concentration of SAA 
rises within hours and a short half life of SAA, it has to be measured subsequently. Hasan et al. showed 
that an inducible transgene expression is detectable one day following doxycycline withdrawal (127). 
Therefore the concentration of SAA was measured in the serum of Lap-tTA+/L-gp130+ dtg mice 24 h 
and 48 h after doxycycline withdrawal. The blood was collected via tail vein punctation and the serum was 
analyzed using a murine SAA ELISA (Invitrogen), including internal controls. No SAA was detectable in 
the serum samples obtained from Lap-tTA+/L-gp130+ dtg mice (data not shown). 
4.2.9 Hydrodynamic injection of pBI5-L-gp130 into Lap-tTA+ tg mice 
To test the inducibility of the expression plasmid pBI5-L-gp130 in vivo it was introduced into Lap-tTA+ tg 
mice via hydrodynamic injection (in cooperation with the group of Prof. Eithan Galun, Goldyne Savad 
Institute of Gene Therapy, Jerusalem, Israel). Hydrodynamic injection is used to introduce DNA into 
hepatocytes in vivo (137). Plasmid DNA was diluted in a high volume and injected into the tail vein in a 
short time (1 ml/10-20 sec) leading to a transient, liver restricted expression of the transgene. Wildtype 
mice were used as control and were co-injected with pBI5-L-gp130 and pTan-Pur, expressing the 
transactivaor tTA. Bioluminescence of injected mice was measured in vivo at day 1, day 2 and day 6 via 
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injection of luciferin and imaging using a CCD camera (Fig. 4.35 A). At day 1 all tg mice showed induction 
of luciferase activity, whereas the evaluation of bioluminescence of wildtype mice showed higher intensity 
compared to Lap-tTA+ tg mice. At day 2 the expression of luciferase in Lap-tTA+ tg mice was twofold 
higher than in wildtype mice, which remained until day 6 (Fig. 4.35 A, B). According to these data an 
inducible expression of luciferase in the liver can be achieved via hydrodynamic injection of pBI5-L-gp130 
in Lap-tTA+ tg mice as well as in wildtype mice, which were co-injected with an expression plasmid for 
tTA (pTan-Pur). Nevertheless, the detected luciferase level is 500-fold higher compared to luciferase 
activity measured in livers of L-gp130+/Lap-tTA+ dtg mice after induction. 
 
 
Figure 4.35: In vivo imaging of Lap-tTA
+
 tg and wt mice following hydrodynamic injection of 
pBI5-L-gp130. (A) Wildtype mice (n=2) were injected with 5 µg of each pBI5-L-gp130 and the Tet-off 
vector pTan-Pur. Lap-tTA tg mice (n=2) were injected with 5 µg pBI5-L-gp130. Bioluminescence was 
measured in livig mice at day 1, 2 and 6 using a CCD camera. (B) Luciferase activity in the livers of 
injected mice was quantified at day 1, 2 and 6 after injection. Experiments were done in cooperation 
with the Goldyne Savad Institute of Gene Therapy, Jerusalem. 
In order to further analyze the expression of L-gp130 in the livers of injected mice, RNA was isolated 
from liver samples obtained from two injected Lap-tTA+ tg mice and two wildtype mice. The 
corresponding cDNA was analyzed by RT-PCR. The transcript of tTA was detectable in Lap-tTA+ tg 
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mice at low levels as well as the transcript of luciferase (Fig. 4.36 A, B). However, the transcript for 
L-gp130 was not detectable in the liver of Lap-tTA+ tg mice (Fig. 4.36 B). Analysis of injected wildtype 
mice showed no expression of L-gp130, luciferase or tTA indicating that the expression of genes 
introduced via hydrodynamic injection in wildtype mice was not detectable via RT-PCR. 
 
Figure 4.36: Analysis of gene expression  for tTA, luciferase and L-gp130 in the liver via 
RT-PCR. The liver RNA of hydrodynamically injected wildtyp (wt) and Lap-tTA
+
 (tg) mice was 
analyzed for transcription levels of the indicated genes. (A) RT-PCR of liver cDNA for tTA and beta-
actin. cDNA of HepG2 cells transfected with tTA was used a control  for tTA. The house keeping gene 
beta-actin served as endogenous control. (B) RT-PCR of liver cDNA for luciferase and L-gp130. 
cDNA of HepG2 cells co-transfected with GFP or L-gp130 and tTA was used a control.  
4.2.10 Analysis of Lap-tTA+ tg mice via Tet-reporter mice 
Since we did no detect any transgene induction in Lap-tTA+/L-gp130+ dtg mice, but determined the 
functionality of the construct pBI5-L-gp130 in vitro and in vivo, we further tested Lap-tTA+ tg mice for the 
functionality of the transactivator. Therefore, Lap-tTA+ tg mice were bred with LC-1 reporter mice (126), 
which express firefly luciferase and Cre-recombinase under control of the tetracycline responsive 
promoter element (TRE). Three Lap-tTA+/LC-1+ dtg mice and control mice (wt, tg) were analyzed for 
luciferase activity in the liver but only one of the dtg mice showed expression of luciferase (Fig. 4.37). This 
result indicates that the transactivator tTA can initiate the gene expression of luciferase in vivo, which is 
under control of the tetracycline responsive promoter element. However, the expression of the 
transactivator in Lap-tTA+ tg mice is not homogenous within this strain because not all Lap-tTA+/LC-1+ 
dtg mice showed detectable levels of luciferase. 
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Figure 4.37: Luciferase activity in the liver of Lap-tTA
+
/LC-1
+
 dtg mice. Lap-tTA
+
 tg mice were 
bred with LC-1
+
 reporter mice, expressing luciferase and Cre-recombinase under control of TRE, to 
test the expression of tTA in the liver. Liver lysates of Lap-tTA
+
 tg, wt and Lap-tTA
+
/LC-1
+
 dtg mice 
were analyzed for the expression of luciferase in the liver using luciferase assay (Promega). RLU: 
relative light units. 
4.2.11 Analysis of L-gp130+ tg mice via Tet-on mice 
L-gp130+ tg mice were analyzed regarding tetracycline responsive promoter (TRE) activity. Therefore we 
switched to the Tet-on system and L-gp130+ tg mice (L2) were bred with hCMV-rtTA+ tg mice, 
expressing the reverse tetracyclibe transactivator (rtTA) under control of a ubiquitous promoter. The gene 
expression of L-gp130 and firefly luciferase in hCMV-rtTA+/L-gp130+ dtg mice was induced by 
doxycycline given via nutrition. Initially, hCMV-rtTA+/L-gp130+ dtg and control mice (wt, tg) were 
analyzed 48 h after doxycycline treatment for luciferase activity in different tissues. 
hCMV-rtTA+/L-gp130+ dtg mice showed expression of luciferase in different tissues as described for the 
hCMV-promoter (126). Based on our data, tissues with different expression levels of luciferase were 
distinguished as followed: low expressing tissues liver, lung and spleen (< 2 x10³ RLU), moderate 
expressing tissues heart, thymus and kidneys (< 20 x10³ RLU) and high expressing tissues skin and 
stomach (> 200 x10³ RLU). Single transgenic hCMV-rtTA+ and L-gp130+ tg mice as well as wildtype mice 
did not show any detectable luciferase activity (Fig. 4.38). Furthermore we analyzed 
hCMV-rtTA+/L-gp130+ dtg mice receiving doxycycline via nutrition for 7 days. Luciferase activity in the 
different tissues was detectable in three out of four double transgenic mice. The three 
hCMV-rtTA+/L-gp130+ dtg mice showed comparable activity of luciferase in the low, moderate and high 
expressing tissues as mentioned before. Only one dtg mouse exclusively showed luciferase induction in 
the skin. Less background luciferase activity was detectable in one L-gp130+ tg mouse. Wildtype as well as 
hCMV-rtTA+ tg mice showed no luciferase activity at all (Fig. 4.38). In addition, we analyzed 
hCMV-rtTA+/L-gp130+ dtg mice, which received doxycycline via nutrition for 2 months. Here, luciferase 
expression was detectable in one out of three dtg mice. Luciferase expression levels did not increase due 
to the longer induction time (data not shown). No expression of L-gp130 was detectable neither in 
Western blot nor in RT-PCR, although luciferase and L-gp130 should be equally expressed due to the 
bidirectional promoter (data not shown). 
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Figure 4.38: Analysis of luciferase activity in different tissues of hCMV-rtTA
+
/L-gp130
+
 (L2) dtg 
mice. Tissue lysates were analyzed for luciferase expression, following 48  h or 7 days of Dox 
treatment via luciferase assay (Promega). hCMV-rtTA
+
/L-gp130
+ 
double transgenic (dtg) mice 
showed an expression of luciferase in selected tissues, whereas no luciferase activity was detectable 
in single transgenic (tg) and wildtype (wt) mice. According to different luciferase expression levels 
the analyszed tissues were grouped into low, moderate and high expressing tissues.  RLU: relative 
light unit. 
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Taken together, luciferase expression was detectable in many tissues of hCMV-rtTA+/L-gp130+ dtg mice. 
Nevertheless not all dtg mice showed an expression of luciferase due to doxycycline treatment. Moreover, 
no further increase of luciferase activity was detected due to a longer induction period by doxycycline 
treatment.  
4.2.12 Generation of Lap-rtTA+/L-gp130+ dtg mice 
As hCMV-rtTA+/L-gp130+ dtg mice resulted in a robust luciferase expression, due to Dox treatment, we 
generated Lap-rtTA+/L-gp130+ (L2) dtg mice to achieve a liver specific expression of L-gp130. Double 
transgenic mice received doxycycline in varying concentrations and time intervals to achieve a sufficient 
induction of the transgene (Tab. 4-3).  
Table 4-3: Doxycycline concentrations and administration for Lap-rtTA
+
/L-gp130
+
 dtg mice. 
Four experimental settings were done as indicated. 
Experiment Nutrition Dox concentration Duration  
1 food 1 g/kg 6 days 
2 food 1 g/kg 13 days 
3 water (+ 3% sucrose) 2 mg/ml 6 days 
4 i.p. injection 2 mg/0.5 ml 6 h 
Independently of the doxycycline treatment parameters in the performed experiments, no induction of 
luciferase activity was detectable in the livers of Lap-rtTA+/L-gp130+ dtg mice. Even following i.p. 
injection of Dox, which is used for a short time induction, luciferase expression was undetectable 
(Fig. 4.39 A) (126). Furthermore, the expression of L-gp130 and rtTA could not be detected by Western 
blot (data not shown). Nevertheless, the rtTA transcript was detectable in the liver of Lap-rtTA+ tg mice 
by RT-PCR, confirming that the mRNA of the activator was expressed (Fig. 4.39 B). 
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Figure 4.39: Analysis of Lap-rtTA
+
/L-gp130
+
 (L2) dtg mice. (A) Expression of luciferase in the 
livers of Lap-rtTA
+
/L-gp130
+
 dtg, L-gp130
+
 tg and wildtype (wt) mice 6 h post i.p. injection of Dox via 
luciferase assay (Promega). RLU: relative light unit. (B) RT-PCR of liver tissue cDNA of Lap-rtTA
+
 tg 
and wt mice for the transcript of rtTA. The house keeping gene beta-actin served as endogenous 
control.  
4.2.13 Analysis of doxycycline concentration in mouse serum 
The serum of treated mice was tested in vitro to analyze, if the doxycycline concentration of the serum was 
sufficient to initiate gene expression. Therefore, HEK 293T cells were transfected with the plasmids 
hCMV-tTA and pBI5-L-gp130. An appropriate amount of doxycycline would inhibit the transgene 
expression using the Tet-off system. Cells, covered with 1 ml of culture medium, were incubated with 2 µl 
of mouse serum obtained from the experiments listed in Tab. 4-3 and analyzed for luciferase activity. The 
serum from mice, which obtained 2 mg/ml Dox in drinking water (exp. 3) led to the strongest but not 
significant decrease of luciferase activity, compared to cells treated with doxycycline (1 µg/ml) 
(Fig. 4.40 A). This experimental setting was repeated vice versa. Therefore HEK 293T cells were transfected 
with the plasmids hCMV-rtTA and pBI5-L-gp130 and 10 µl of mouse serum was added to 1 ml culture 
medium. Doxycycline would induce the transgene expression using the Tet-on system. The strongest 
induction of luciferase expression was achieved with serum from mice injected i.p. with 2 mg doxycycline 
(exp. 4, Fig. 4.40 B). However, the luciferase activity of transfected cells was 10-times reduced compared 
to cells treated with a defined doxycycline concentration (1 µg/ml). These data revealed that the content 
of doxycycline in the serum of treated mice was sufficient to activate or inhibit inducible gene expression 
in vitro and indicated a comparable effect in vivo as well. 
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Figure 4.40: In vitro test of doxycycline concentration in serum of Dox treated mice. HEK 293T 
cells were transfected either with (A) hCMV-rtTA and pBI5-L-gp130 (Tet-on system) or (B) 
hCMV-rtTA and pBI5-L-gp130 (Tet-off system). Cells were incubated 48 h post transfection with 
mouse serum obtained from the experiments listed in Tab. 4-3 and were tested for luciferase activity 
after incubation of 24 h via luciferase assay (Promega). RLU: relative light unit. 
To sum up, we could detect an inducible expression of L-gp130 due to doxycycline in vitro. Using 
L-gp130+ tg mice no transgene expression was obtained in vivo even though different mice expressing the 
transactivator in the liver were used to generate dtg mice. 
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5 DISCUSSION 
5.1 Mutations in the IL-6 contact site of gp130 influence its activation 
Activation of the cytokine receptor subunit gp130 is induced by IL-6 and corresponding cytokines of the 
IL-6 family. Thereby, IL-6 is a well known regulator of inflammation, autoimmune diseases and tissue 
regeneration (22, 138).  Detailed mechanisms how cytokine binding to gp130 leads to activation of the 
intracellular associated Janus kinases is barely understood. Crystal structures and electron microscopy 
studies of gp130 (in complex with vIL-6 as well as with the IL-6/sIL-6R complex) revealed crucial 
interaction sites of the first three domains D1 to D3 of gp130 and defined three binding sites generated by 
the IL-6/IL-6R complex and two molecules of gp130 (5, 107). Recently, activating deletion mutations of 
gp130 have been discovered in patients with benign liver tumors, which were present in 60% of human 
inflammatory hepatocellular adenoma (IHCA) (121). Despite the knowledge that the mutations found in 
IHCAs were located in domain D2 of gp130, which represents the binding interface to IL-6, the structural 
mechanism of ligand independent gp130 activation is completely unknown. One frequently found deletion 
comprises the residues Y186 to Y190 (ΔYY) and was generated in our laboratory to investigate the 
functional and structural characteristics of ligand independent activation (Fig. 4.12 A) (133). 
Based on the current crystal structure of the IL-6/sIL-6R/gp130 complex we assumed that a displacement 
or deletion of crucial residues around the EF loop of domain D2 results in ligand independent activation 
(139). We realized that the EF loop is stabilized by a disulfide bridge formed by C172 and C182, as well as 
by an ionic interaction of D215 to the backbone of the EF loop. We speculate that destabilization of the 
EF loop may result in aberrant signaling. Therefore we substituted the residues at position C172 and 
D215 in order to achieve molecular instability. We could show that the substitutions C172S and D215G 
led to ligand independent activation of gp130 in HEK 293T, HepG2 and Ba/F3-gp130 cells, which was 
monitored by STAT3 phosphorylation, STAT3 dependent proliferation and a STAT3 reporter assay. In 
cooperation with Martin Zacharias (Physics Department, TU Munich) we performed furthermore 
molecular dynamics simulations (100 ns) on gp130 wt, gp130 C172S and gp130 D215G to test our 
hypothesis that the described mutants enhance the EF loop flexibility. As a read out the D2/D3 
interdomain angle flexibility and conformational fluctuations at the D2/D3 domain interface were 
recorded. We observed an increased rotamer flexibility of selected amino acid sidechains, which might 
result from an increased EF loop flexibility as well as an increased D2/D3 interdomain flexibility (data not 
shown). Given these data, the proper positioning of the EF loop in domain D2 seems to be crucial for an 
inactive gp130 conformation and interference results in activation (Fig. 5.1). We were interested if those 
mutations would alter constitutive activity of the gp130 ΔYY deletion mutant and introduced the point 
mutations C172S and D215G in the gp130 ΔYY mutant. Measuring gp130 activation by means of STAT3 
phosphorylation, proliferation and activation of a STAT3 reporter, we could determine a slight decrease in 
ligand independent activation of the gp130 ΔYY mutant due to the substitution C172S. We wondered 
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why the mutation C172S led to ligand independent activation of gp130 wildtype but to diminished 
activation of the gp130 ΔYY mutant. We speculated that the disulfide bond formed by the residues C172 
and C182 in gp130 wildtype is not present in the deletion mutant gp130 ΔYY, and that those cysteines 
could form alternative even intermolecular disulfide bonds instead, which are involved in the constitutive 
activity of the deletion mutant gp130 ΔYY. Therefore, we analyzed the influence of DTT, which is a 
strong reducing agent and leads to disruption of disulfide bonds. HEK 293T cells overexpressing the 
gp130 ΔYY mutant or gp130 wt (+ Hyper-IL6) were treated with DTT and lysates were analyzed under 
non-reducing conditions. We observed that DTT treatment led to a diminished phosphorylation of 
STAT3 in both gp130 ΔYY and Hyper-IL6 treated gp130 wt overexpressing cells. An equal reduction of 
STAT3 activity was detected in non treated HEK 293T cells expressing the mutant gp130 ΔYY C172S, 
indicating that disulfide bond formation is crucial for the activation of the gp130 ΔYY mutant (data not 
shown). Nevertheless we can not state at the moment if intermolecular disulfide bond formation is 
involved in gp130 ΔYY activation. So far, we could demonstrate that C172 in the extracellular portion 
contributes to the constitutive activity of the mutant gp130 ΔYY. The substitution D215G did not affect 
the signal transduction of the gp130 ΔYY mutant. 
Moreover, it is unclear why constitutive active mutants of gp130 are not suppressed by endogenous 
inhibitors, such as SOCS3. Gp130 deletion mutants found in human liver adenoma led to upregulation of 
SOCS3 mRNA in comparable levels achieved with IL-6 treatment, but it remains unclear why these 
mutants still display constitutive STAT3 activation (121). When co-expressed with gp130 mutants, SOCS3 
was still able to suppress ligand independent STAT3 phosphorylation, indicating that the gp130 mutants 
are still susceptible to SOCS3 mediated inhibition in vitro. Probably the balance of activating and inhibitory 
signals in vivo is shifted, leading to an incability of SOCS3 to suppress the downstream signaling of gp130 
deletion mutants. 
5.2 Disruption of the hydrophobic D2/D3 connectivity induces gp130 
activation 
Furthermore, we focused on the D2/D3 interface, which connects the D2 EF loop and the D3 BC loop 
through hydrophobic residues. We postulated that interference with the interconnecting hydrophobic 
area, comprising e.g. the amino acids V189, Y190 and V252 promote gp130 activation. This assumption is 
supported by previous reports, showing that the D2/D3 hinge region might function as a ‘molecular 
switch’. The residue V252 is situated in the flexible and most exposed part of the BC loop in domain D3, 
which was revealed by NMR spectroscopy (131). Horsten et al. claimed that the substitution V252D 
destroys the central hydrophobic interaction between gp130 and IL-6. Indeed the mutant gp130 V252D 
showed 50% reduced affinity for the IL-6/sIL-6R complex compared to gp130 wt as well as a strong 
decrease of biological activity (107).  
To underline the importance of this hydrophobic area for gp130 activation, we substituted the residues 
V189, Y190 and V252 and examined the signal transduction of the generated gp130 mutants in HEK 
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293T, HepG2 and Ba/F3-gp130 cells. Neither V189G nor Y190G displayed ligand independent induction 
of STAT3 phosphorylation or STAT3 dependent proliferation. Regarding these data, we conclude that 
substitution of V189 and Y190 did not alter the hydrophobic area and that these residues are not involved 
in gp130 activation. However, the substitution V252G resulted in an autonomous activation of gp130 and 
subsequent STAT3 activation, such as phosphorylation as well as proliferation and activation of a STAT3 
reporter. Taken together, V252 is embedded in the hydrophobic core connecting the BC loop of domain 
D3 with the EF loop of domain D2 and substitution to glycine disrupts the conformation of this D2/D3 
interdomain, resulting in activation of the intracellular associated Janus kinases (Fig. 5.1). Introduction of 
the mutation V252G did not alter the constitutive activity of the gp130 ΔYY mutant, which leads to the 
assumption that the hydrophobic interactions of D2/D3 are already loosened in the gp130 ΔYY mutant.  
 
Figure 5.1: Model of gp130 activation I. Left: The inactive state of gp130 is stabilized by the 
formation of a hydrophobic core (grey) connecting the D2 EF loop (red) with the D3 BC loop (brown), 
limiting their flexibility. Right: Activating mutations either increase flexibility of the D2 EF loop, 
disconnecting it from D3 BC loop (C172S, D215G, deletion mutations) or directly disconnect the two 
loops by disturbing the hydrophobic core (V252G mutation). This leads to a pre-activated state of 
gp130. (Schuett et al., submitted) 
As ongoing work we want to validate the data achieved for the gp130 C172S mutant by replacing the 
counterpart C182. We furthermore generated gp130 mutants containing the substitutions E138A, V184P 
and V192P. The residue E138 exhibits ionic interactions to domain D3 of gp130, as seen in the crystal 
structure and we speculate that interference loosens the D2/D3 connectivity, which subsequently leads to 
activation. The residues V184 and V192 are flanking the EF loop. Substitution to proline, which exhibits a 
strong conformational rigidity, will alter the positioning of the whole loop, resulting presumably in 
autonomous activation of gp130. Moreover, the substitutions F191E and V252D, which lead to impaired 
activation of gp130 wt, will be introduced into the deletion mutant gp130 ΔYY to analyze its constituve 
activity (16, 107). Crystal structure reveals that V252 is partially hidden by the side chain of F191, which is 
located in the EF loop of domain D2, highlighting a connection of these two residues (106, 131). By 
interfering with F191 in domain D2, Planz et al. ruled out the importance of this residue for the IL-6 
binding site II of gp130 (16). The mutation F191E did not interfere with the binding of the IL-6/sIL-6R 
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complex to gp130 but the mutant gp130 F191E was biologically inactive, judged by reporter assays where 
no significant activation of STAT1 was detectable. Co-immunoprecipitation studies revealed that the 
mutant gp130 F191E cannot form homodimers, which were crucial for the transmission of a signal 
transduction cascade (16). This mutation in the background of gp130 ΔYY will be analyzed, with respect 
to its constitutive activity. On the other hand, we generated the mutation F191G, expecting to observe a 
ligand independent activation, as we assumed that this mutation also disrupts the hydrophobic core. 
In addition, Horsten et al. already showed that the substitution V252D led to impaired binding of the 
IL-6/sIL-6R complex compared to gp130 wt as well as to diminished biological activity, determined with 
a reporter assay (107). This underlines the importance of distinct residues in the binding interface of IL-6 
for the activity of gp130. The fact, that replacement of the crucial residue V252 with aspartate led to an 
impaired gp130 signaling, whereas the substitution V252G showed autonomous gp130 activity is very 
interesting. We conclude that the hydrophobic property of valine is changed by introducing the small and 
unpolar residue glycine, whereas the introduction of aspartic acid could lead to alternative polar 
interactions and thereby abrogating gp130 activation. This hypothesis can be tested by the mutants gp130 
F191G and gp130 ΔYY F191E, as well as gp130 ΔYY V252D. 
5.3 Domain D1 is important for gp130 activation but dispensable for 
dimerization 
Previous reports suggest a role of the immunoglobulin-like domain D1 in the binding of IL-6 and gp130 
activation. Pflanz et al. showed that cells expressing gp130 lacking the domain D1 (gp130 ΔD1) were not 
able to bind IL-6/sIL-6R complexes. However, cells co-expressing the mutant gp130 ΔD1 and a gp130 
mutant altered in domain D2 could respond well to IL-6 and soluble IL-6R (16). Therefore, it was 
postulated that domain D1 is absolutely required to initiate signal transduction, and that two different 
epitopes of gp130, one on each receptor chain, are sufficient for binding of the IL-6/sIL-6R complex. 
Obviously, these epitopes are cooperating due to asymmetrical binding of IL-6/sIL-6R. The importance 
of domain D1 for gp130 activation has been further underlined by Sommer et al.. In this study the deletion 
of domain D1 abolished the constitutive activation of the gp130 ΔYY mutant, highlighting that the D1 
domain is involved in ligand independent activation of gp130 ΔYY (133). In this context we were 
interested, if partial deletion of domain D1 is sufficient to abrogate constitutive signaling of the gp130 
ΔYY mutant. Gp130 crystal structure reveals that the N-terminus of domain D1 contacts IL-6 directly 
through intercalation into a groove of IL-6 (Fig. 4.12 B) (112). We assumed that the N-terminus 
contributes to the ligand independent activation of the gp130 ΔYY mutant in the way that domain D1 
contacts a neighboring gp130 with this N-terminal peptide. To address the relevance of the N-terminus 
for gp130 activation, we deleted the first five residues E1 to P5 (ΔN1-5) in the gp130 ΔYY mutant. HEK 
293 T cells expressing the mutant gp130 ΔYYΔN1-5 showed diminished activity of STAT3, in terms of 
phosphorylation, subsequent proliferation and activation of a STAT3 reporter. However, the constitutive 
activation of gp130 ΔYYwas not completely abolished due to the deletion ΔN1-5 as compared to cells 
expressing the mutant gp130 ΔYYΔD1. In addition, we generated mutants, which contain substitutions of 
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only one of these five amino acids (gp130 ΔYY E1A, L2G, L3G, D4A and P5G). None of the mutants 
led to reduced activity of STAT3 compared to the gp130 ΔYY mutant, indicating that a potential 
intermolecular contact is not mediated by a single residue (data not shown). 
We speculate that domain D1 interferes with the binding site II of IL-6, located in the domain D2 of the 
second gp130 molecule. Thereby, the domain D1 pushes the IL-6/IL-6R complex in the D2/D3 groove. 
This pressure leads to a conformational change of this hydrophobic area as well as of the C-terminal part 
of gp130, which leads subsequently to activation of the Janus kinases. It is known that the gp130 ΔYY 
mutant can form homodimers and maybe domain D1 of the gp130 ΔYY mutant is sufficient to push the 
D2/D3 interface of another gp130 molecule without the help of an additional molecule, e.g. the IL-
6/IL-6R complex (Fig. 5.2). The deletion of the N-terminus in the gp130 ΔYY mutant presumably 
reduces the force of domain D1 to exhibit pressure on the loosened D2/D3 interface and leads therefore 
to a reduced STAT3 activation.  
 
Figure 5.2: Model of gp130 activation II. The preactivated state (Fig. 5.1) needs the interaction to 
domain D1 of a second gp130 molecule, anchored by its N-terminal peptide (blue) in order to achieve 
fully fledged activation of gp130. (Schuett et al., submitted) 
This hypothesis can be proven by exchanging the D1 domain of the mutant gp130 ΔYY with globular 
domains (e.g. GFP) of different molecular weights, to monitor which size is adequate to keep the 
constitutive activity of the gp130 ΔYY mutant. The data generated by Sommer et al. showed that blocking 
of the domain D1 by the anti-gp130 antibody B-T2 did not influence autonomous proliferation of cells 
expressing the mutant gp130 ΔYY, whereas deletion of domain D1 led to abrogation of ligand 
independent proliferation (133). In context with our assumption, the anti-gp130 antibody B-T2 has no 
influence on ligand independent proliferation because the domain D1 is still present and can exhibit 
pressure to the D2/D3 interface of another gp130 molecule. Furthermore it is possible that the binding of 
the anti-gp130 antibody B-T2 even increases the tension. But with the complete loss of this plunger, the 
D2/D3 groove is unchanged, resulting in inactivation of the gp130 ΔYYΔD1 mutant. This leads to the 
conclusion, that a sterical correct orientation of domain D1 (or an appropriate domain) and its access to 
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the D2/D3 interface of a second gp130 molecule seems to be important for gp130 activation. It seems 
that the whole domain D1 is needed to achieve the right positioning of the D2/D3 area and subsequent 
activation of gp130, whereas the N-terminal tail of domain D1 helps to properly anchor the domain D1 to 
a second gp130 molecule (Fig. 5.3).  
Moreover, it has been shown that dimerization of the gp130 ΔYY mutant was independent of the 
presence of domain D1, whereas gp130 wt lacking the domain D1 was not able to form homodimers (16). 
Sommer et al. speculated that homodimers of the gp130 ΔYY mutant were built through an interaction of 
the mutated domains D2. We studied the potential of the mutants gp130 ΔYY, gp130 ΔYYΔD1 and 
gp130 ΔYYΔN1-5 to form dimers. Using co-immunoprecipitation, we realized that co-expressed gp130 
variants form homo- as well as heterodimers irrespective of their partners. All precipitated receptors 
showed phosphorylation of tyrosine residues, indicating that co-expression results in activation of gp130. 
Furthermore, we could show that the generated constitutive active mutants gp130 C172S, gp130 D215G 
and gp130 V252G were able to form homodimers and in consequence showed phosphorylation of 
tyrosine residues as well as activation of STAT3. Furthermore, we reproduced data showing that gp130 wt 
forms inactive homodimers. We hypothesize that the formation of homodimers is not sufficient to 
activate gp130 but rather the interference with the hydrophobic core of D2/D3 is crucial for the 
activation of associated Janus kinases and gp130 downstream signaling (Fig. 5.2, 5.3). 
 
Figure 5.3: Schematic representation of gp130 signaling complexes. (A) The hexameric 
IL-6/IL-6R/(gp130)2 complex, indicating the involvement of the gp130 D1 domain in contacting IL-6. 
In red are highlighted the first five N-terminal amino acids in gp130 D1 domain. (B) Potential dimer 
formation and ligand independent activation of gp130 deletion mutants like gp130 ΔYY. Areas of 
deletions are depicted in yellow. Domain D1 of gp130 is contacting the site of mutation.  (Schuett et 
al., submitted) 
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5.4 Expression of the constitutive active variant L-gp130 can be achieved 
in vitro and ex vivo using an inducible system 
As reported by Stuhlmann-Laeisz et al. the expression of the constitutive active variant L-gp130 leads to 
sustained phosphorylation of STAT3 in HepG2 cells, ligand independent proliferation of Ba/F3-gp130 
cells and suppresses the in vitro differentiation of murine embryonic stem cells (123). We took advantage 
of the Tet-system in order to achieve inducible expression of L-gp130 and firefly luciferase. Both systems, 
inhibition (Tet-off) and induction (Tet-on) of gene expression via doxycycline treatment were analyzed in 
vitro and in vivo.  We could show in time course experiments that an induction time of 24 h is sufficient for 
both systems in vitro. Furthermore, we defined in a dose response curve that 1 µg/ml doxycycline is an 
adequate concentration for the induction of gene expression. 
Transgenic mice expressing L-gp130 and firefly luciferase under the control of the tetracycline responsive 
promoter element (TRE) were generated in cooperation with the IBF (Heidelberg). Twelve L-gp130+ 
strains were established, which presumably differ in site and amount of transgene integration. In order to 
find out, if expression of L-gp130 and luciferase can be induced via the Tet-system ex vivo, we generated 
murine embryonic fibroblasts (mEF cells) of L-gp130+ tg mice. MEF cells from one L-gp130 strain (L11) 
showed luciferase activity in the absence of the transactivator, indicating a leakiness of the Tet-promoter. 
Consequently, mEF cells of different L-gp130 strains were stably transduced with the transactivator tTA 
and analyzed for L-gp130 and luciferase expression. Two out of four generated mEF cell lines from 
L-gp130+ strains L2 and L5, showed transgene induction in response to tTA, which could be inhibited by 
doxycycline treatment. We assumed that these mouse strains (L2, L5) are suitable for breding with 
Tet-mice, expressing tTA or rtTA under the control of a tissue specific promoter. 
5.5 Different Tet-inducer strains failed to induce the expression of 
L-gp130 and firefly luciferase in vivo due to promoter inactivity 
We wanted to investigate the cell-autonomous activation of L-gp130 in the liver of transgenic mice, 
because previous reports showed that transgenic mice expressing IL-6 and sIL-6R in the liver developed 
liver hyperplasia and adenoma but no malignant tumors (51, 140). The same was reported for the gp130 
deletion mutants found in human liver adenoma, which seem to be insufficient to induce malignant tumor 
formation. Initially, we analyzed luciferase activity in liver lysates of L-gp130+ tg mice and detected 
background activity in two strains (L11 and L12). This result stands in line with the data obtained from 
L-gp130+ mEF cells, indicating that the site of integration causes probably a leakiness of the promoter. To 
analyze the induction of L-gp130 expression in vivo, different L-gp130+ tg mice strains were crossed with 
mice expressing the tetracycline transactivator (tTA) under control of the liver-enriched activator protein 
(Lap) promoter (Lap-tTA+ tg mice). All mice, including breeding pairs, were kept on doxycycline 
supplemented nutrition for 3 - 8 weeks to prevent activation of L-gp130 at early stage, as it is known that 
gp130 is highly expressed in the murine uterus at day 3 and 4 of pregnancy and is essential for the 
implantation of mouse embryos in combination with the LIF receptor (141). Following an induction time 
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of 1 to 16 weeks, mice were analyzed at the age of 3 to 6 months. However, Lap-tTA+/L-gp130+ dtg mice 
did not show any expression of L-gp130 in the liver. In addition, luciferase expression was examined 
either in liver lysates or via in vivo imaging using a CCD camera. Induction of luciferase expression was 
absent in control mice, whereas the expression of luciferase in Lap-tTA+/L-gp130+ dtg mice was very 
low. However, literature reveals that luciferase expression needs to reach a specific threshold to ensure 
transgene expression, even if both genes are expressed under control of a bidirectional promoter element. 
Ernst et al. generated transgenic mice expressing a core protein of the hepatitis virus C as well as firefly 
luciferase under control of the Tet-specific promoter. These mice were crossed to Lap-rtTA+ tg mice to 
achieve liver specific expression. They could examine that low luciferase activity correlates with 
undetectable protein levels of the transgene in Western blot analysis (142). Another reason for low or 
absent induction could be the long term treatment with doxycycline, which prevented transgene 
expression in early stages. It is postulated that doxycycline can be incorporated into the bones or the fat 
tissue, thereby building depots from where it is released at later time points (K. Schönig, ZI Mannheim, 
personal communication). Even low concentrations of doxycycline are enough to suppress transgene 
expression in the very sensitive Tet-off system. Due to undetectable levels of the tTA transcript in liver 
lysates of Lap-tTA+ tg mice, we assumed that the transactivator is either not expressed or did not reach an 
appropriate concentration to induce gene expression. Crossing Lap-tTA+ tg mice with LC-1 reporter mice, 
expressing luciferase and Cre-recombinase under control of the Tet-promoter, revealed that only one out 
of three Lap-tTA+/LC-1 dtg mice showed luciferase induction. This data leads to the conclusion that the 
transactivator tTA is not homogenously expressed among the population of Lap-tTA+ tg mice. 
In cooperation with the group of Prof. Eithan Galun (Goldyne Savad Institute of gene therapy, Jerusalem, 
Israel) we analyzed the expression of the L-gp130 construct (pBI5-L-gp130) in the liver of Lap-tTA+ tg 
mice via hydrodynamic injection. As control, wildtype mice were co-injected with pBI5-L-gp130 and a 
Tet-off vector (pTan-Pur). Mice were imaged for luciferase expression in vivo up to 6 days via CCD 
camera. The injected Lap-tTA+ tg mice showed stronger and persistent expression of luciferase as 
compared to injected wildtype mice. These data indicate that the expression of L-gp130 can be induced in 
the liver via the tetracycline transactivator (tTA). However, by using hydrodynamic injection the number 
of gene copies is increased compared to transgenic mice, resulting in higher transgene expression. 
Furthermore, hydrodynamic injection leads only to a transient and not to a stable integration of the 
transgene in the liver such as in transgenic mice. We therefore conclude that the genomic integration in 
L-gp130+ tg mice might impair the inducibility of the Tet-promoter. 
For further experiments, we switched to the Tet-on system to avoid long doxycycline treatment. Using 
this system, comparable induction levels of L-gp130 and luciferase expression were achieved in vitro. The 
L-gp130+ strain L2 was the most suitable to generate double transgenic mice, because mEF cells isolated 
of this strain were responsive to retrovirally transducted tTA. Initially, L-gp130+ tg mice (L2) were crossed 
to hCMV-rtTA+ tg mice to analyze the induction capability of the Tet-promoter via the reverse 
transactivator (rtTA) in general. To induce transgene expression, hCMV-rtTA+/L-gp130+ dtg  mice were 
treated with doxycycline for 48 h, 7 days or up to 2 months and luciferase activity was detectable in several 
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tissues, as reported by Schönig et al. (126). However, no increase in luciferase expression due to long term 
induction could be detected and no expression of L-gp130 was measurable in any tissue. For liver tissue, 
this can be explained with the reduced activity of the hCMV promoter in hepatocytes. For other tissues 
however this might indicate a transcriptional silencing due to genomic integration. To analyze liver specific 
expression, L-gp130+ mice were crossed with Lap-rtTA+ tg micge and Lap-rtTA+/L-gp130+ dtg  mice 
received doxycycline for one or two weeks to induce gene expression (143). However, no expression was 
detectable for L-gp130 and luciferase in Western blot analysis and luciferase assay, respectively. Even high 
dose i.p. injection of doxycycline into double transgenic mice did not result in the induction of the Tet-
promoter. Although the expression of the reverse tetracycline transactivator (rtTA) was shown by RT-
PCR and doxycycline was detectable in the sera of treated mice, the transgene expression was not induced. 
This leads to the conclusion that the Tet-promoter is not accessible for rtTA. We hypothesized that the 
random integration site of the transgene causes probably a silencing of the Tet-promoter by e.g. 
methylation. 
Due to the fact that the generated L-gp130+ tg mice were not capable to express the transgene in an 
inducible manner, this strain was terminated. New mice will be generated in the future in cooperation with 
T. Wunderlich (Cologne). A transgene containing a 5' floxed stop cassette followed by the L-gp130 cDNA 
will be introduced into the Rosa26 locus. Expression of L-gp130 will be induced by the Cre-mediated 
removal of the stop cassette. The liver specific expression of constitutive active L-gp130 will then be 
achieved using mice expressing Cre-recombinase in hepatocytes (e.g. Alfp-Cre, Alb-Cre). The liver will be 
the focus of further investigations, in respect to analyze formation of liver adenoma and liver regeneration 
after injury. As shown by Jenkins et al., expression of constitutive active gp130 in mice resulted in gastric 
hyperproliferation and growth of spontaneously arising gastric adenomas (101). We expect an equal effect 
in the liver due to liver restricted expression. Previous studies revealed that IL-6 and gp130 play an 
essential role in liver regeneration as well as in tumor initiation. In addition, mice expressing the deletion 
mutant gp130 ΔYY in the liver are under ongoing investigation in our laboratory.  
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Taken together, to the best of our knowledge we present here for the first time data which helps to 
understand the molecular basis of gp130 activation. We could show that activating mutations increase the 
flexibility of the EF loop situated in domain D2. As a consequence hydrophobic interactions to domain 
D3 are lost, leading to the transmission of the activating signal via domains D4-D6 to the intracellular 
part. Further structure-function analyses as well as crystallisation of the deletion mutant gp130 ΔYY are 
needed to fully understand the mechanism of gp130 activation.  
Although the participation of IL-6 and gp130 signaling to liver diseases has been shown, the consequences 
of a cell-autonomous hepatocellular gp130 activation are unclear. We therefore sought to develop a 
transgenic murine model system with a tetracycline-inducible expression of a constitutive active gp130 
variant. Unfortunately our model hampered inducible expression so that we cannot draw any conclusions 
from the current mouse model. Therefore we are currently developing novel approaches to generate 
transgenic mice with hepatocellular expression of ligand independent gp130 variants. With those models 
we hope to deepen our knowledge about the participation of gp130 signaling in liver regeneration and 
liver tumor formation, resulting in novel concepts for therapeutic interventions. 
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6 SUMMARY 
The IL-6 cytokine family is involved in inflammation, regeneration and tumor formation (23, 144). One 
characteristic of IL-6 signaling is the requirement of the alpha-subunit IL-6R, which exists as a membrane 
bound as well as a soluble form. The IL-6/IL-6R complex binds to the ubiquitously expressed, signal 
transducing beta-receptor gp130, leading to gp130 activation and downstream signaling via the 
intracellular associated Janus kinases (JAKs). Despite the fact that the binding sites of the IL-6/IL-6R 
complex to gp130 were identified by crystal structure analysis, the molecular mechanism underlying gp130 
activation is barely understood.  
Recently constitutive active deletion mutants of gp130 were found in patients with benign liver adenoma. 
Theses deletions differ in length as well as in position and cluster around the IL-6 contact site of domain 
D2. This contact area comprises the EF loop, stabilized by adjacent amino residues in wildtype gp130. 
Furthermore, the EF loop is connected to the BC loop of domain D3 via hydrophobic interactions. We 
hypothesized that an inactive gp130 conformation is stabilized via such interactions. Using a rational 
structure-based mutagenesis approach we could show, that an increased EF loop flexibility as well as 
interference with the hydrophobic interactions led to ligand independent activation of gp130. In addition 
we discovered that the D1 domain, in particular the first N-terminal residues were crucial for the ligand 
independent activity of the gp130 deletion mutants. Based on our results we present a model, which helps 
to explain the molecular basis of cytokine dependent as well as cytokine independent activation of gp130, 
presumably providing an insight into the molecular basis of cytokine receptor activation in general. 
Moreover, we were interested in the physiological consequences of a cell-autonomous, ligand independent 
activation of gp130 in hepatocytes. We therefore generated transgenic mice, expressing a previously 
published artificial, constitutive active variant of gp130 (L-gp130) in a tetracycline inducible manner. We 
intended to use this murine model to study in more depth the impact of hepatocellular signaling on 
injury-induced liver regeneration and tumor promotion. Unfortunately we did not achieve an inducible 
expression of L-gp130 during our analysis, suggesting that the transgene was silenced after genomic 
integration. Therefore we are currently generating two alternative murine models to analyze the effect of a 
cell-autonomous hepatocellular expression of ligand independent gp130 variants. 
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7 ZUSAMMENFASSUNG 
Die Familie der Interleukin-6 (IL-6) Zytokine spielt eine wichtige Rolle bei Entzündung, Regeneration und 
Tumorentstehung (23, 144). Die Besonderheit der IL-6 Signalgebung ist, dass IL-6 zuerst an seinen alpha-
Rezeptor (IL-6R) binden muss, welcher in membrangebundener und löslicher Form existiert. Dieser 
Komplex bindet an den ubiquitär expremierten, signalgebenden beta-Rezeptor gp130 und aktiviert die 
intrazellulär gekoppelten Janus kinasen (JAKs). Obwohl die Bindungsstellen des IL-6/IL-6R Komplexes 
an gp130 anhand von Strukturanalysen aufgeklärt wurden, ist die molekulare Grundlage der gp130 
Aktivierung nach wie vor unklar.  
Kürzlich wurden konstitutiv aktive Deletionsmutanten von gp130 in Patienten mit benignen 
Leberadenomen gefunden (130). Die Deletionen variierten in Länge und Position, befanden sich jedoch 
alle in einem Bereich der D2 Domäne, die als Kontaktstelle für IL-6 identifiziert wurde. Dieser Bereich 
beinhaltet den EF loop, dessen Konformation durch angrenzende Aminosäuren in Wildtyp gp130 
stabilisiert wird. Zudem ist der EF loop über hydrophobe Wechselwirkungen mit dem BC loop der D3 
Domäne verbunden. Wir stellten die Hypothese auf, dass eine inaktive gp130 Konformation durch diese 
Wechselwirkungen stabilisiert wird. Durch rationale strukturbasierte Mutagenese konnten wir zeigen, dass 
eine erhöhte Flexibilität des EF loops, als auch die Unterbrechung der hydrophoben Interaktionen zu 
einer liganden-unabhängigen Aktivierung von gp130 führten. Zudem können wir zeigen, dass die D1 
Domäne und insbesondere die ersten N-terminalen Aminosäurereste eine wichtige Rolle bei der liganden-
unabhängigen Aktivierung der gp130 Deletionsmutanten spielt. Aufgrund unserer Befunde können wir ein 
Modell aufstellen, das versucht, die molekularen Grundlagen der Zytokin-abhängigen, als auch der 
Zytokin-unabhängigen gp130-Aktivierung zu erklären und somit einen generellen Einblick in die 
Aktivierung von Zytokinrezeptoren liefert. 
Wir waren zudem an den physiologischen Konsequenzen einer zell-autonomen, liganden-unabhängigen 
hepatozytären gp130 Aktivierung interessiert. Wir generierten daher transgene Mäuse mit einer 
Tetrazyklin-induzierbaren Expression einer kürzlich publizierten artifiziellen, konstitutiv aktiven gp130 
Variante (L-gp130). Die Auswirkungen auf die Leberregeneration nach Schädigung, sowie die Entstehung 
von Lebertumoren sollten anhand dieses murinen Modells ermittelt werden. Im Laufe unserer Analysen 
zeigte sich allerdings, dass die L-gp130 Expression nicht induzierbar war und der Promotor vermutlich im 
Genom nicht zugänglich vorliegt. Wir arbeiten daher gerade an zwei alternativen transgenen 
Mausmodellen zur zell-autonomen Expression liganden-unabhängiger gp130 Varianten. 
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9 APPENDIX 
9.1 Abbreviations 
A 
Aa   Amino Acid  
Ab   antibody 
ADAM   A Disintegrin and Metalloprotease 
APP   Acute Phase Protein 
APR   Acute Phase Response 
APS   Ammonium persulfate 
Asp   Aspartatic Acid 
B 
BiFC   bimolecular fluorescence complementation  
bp   Base Pairs  
BSA   Bovine Serum Albumin 
C 
CBM   Cytokine Binding Module  
cDNA    Complementary DNA  
CIAP        Calf Intestine Al kali ne Phosphatase 
CLC   Cardiotrophin-Like Cytokine  
CNTF   Ciliary Neutrotrophic Factor 
CRP   C-Reactive Protein  
CT-1   Cardiothrophin-1 
Cys   Cysteine 
D 
dl   Deciliter  
DNA   Deoxyribonucleic Acid  
dNTP   2’-Desoxyribonucleotide-5’-Triphosphate  
Dox   Doxycycline 
DTT   Dithithreitol 
E 
EAE   Experimental Autoimmune Encephalomyelitis  
ECD   Extracellular domain 
ECL   Electrochemiluminescence  
EDTA    Ethylenediaminetetraacetic Acid  
EGTA   Ethylene glycol tetraacetic acid 
ELISA   Enzyme Linked Immunosorbent Assay  
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ERK   Extracellular Signal Regulated Kinase  
F 
FACS   Fluorescence Activated Cell Sorter  
Fc   Fragment Crystallizable  
f.c.   final concentration 
FCS   Fetal calf serum 
FN III   Fibronectin Type III 
FRET   Förster resonance energy transfer 
G 
GFP   green fluorescent protein 
Glu   Glutamic Acid 
gp130    Glycoprotein 130  
GPL   gp130-like receptor 
Grb2   Growth Factor Receptor Bound Protein 2 
H 
H   Hour  
hCMV   Human cytomegalie virus 
HEPES   2-(4-(2-Hydroxyethyl)-1-piperazinyl)-ethansulfonsäure 
HepG2   hepatocellular carcinoma 
HEK   human embryo kidney 
HIL-6   Hyper-IL-6 
I 
ICD   Intracellular Domain 
IgD   Immunoglobulin-like Domain  
IL   Interleukin  
IL-6R   Interleukin-6 Receptor  
IP   Immunoprecipitation 
i.p.   Intraperitoneal Injection  
IVC   Isolated Ventilated Cages 
J  
JAK   Janus kinase 
K 
kb   Kilobase Pairs  
kDa   Kilodalton  
kg   Kilogram 
L 
L   Liter  
LB   Lysogeny Broth 
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Lap   Liver enriched activator protein 
LIF   leukemia inhibitory factor 
Luc   Luciferase 
M 
mAb   Monoclonal Antibody 
MAPK   Mitogen-activated protein kinase 
mEF   Mouse embryonic fibroblasts 
mIL-3   Murine interleukine-3 
min   Minute  
mg   Milligram  
ml   Milliliter  
mRNA   Messenger RNA  
MTT   3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
µ   micro 
N 
NaF   Sodium fluoride 
Na3VO4    Sodium orthovanadate 
NP   Neuropoietin  
NP-40   nonyl phenoxypolyethoxylethanol 
n.t.   non-transfected/ non-transduced 
O 
OD   Optic Density  
OSM   Oncostatin M 
P 
Phe   Phenylalanine 
Pen/ Strep   Penicillin/ Streptomycin 
P6   Pyridone 6 
PBS   Phosphate Buffered Saline  
PCR   Polymerase Chain Reaction  
PMSF   Phenylmethanesulfonylfluoride 
POD   Peroxidase  
Pro   Proline 
P-STAT3   Phospho-STAT3  
PVDF   Polyvinylidene Fluoride 
R 
RA   Rheumatoid Arthritis  
RNA   Ribonucleic Acid  
RLU   Relative light units 
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RT   Room Temperature  
RT-PCR   Reverse Transcriptase PCR 
S 
SAA   Serum Amyloid A 
SDS   Sodium Dodecyl Sulfate 
Ser   Serine 
SFM   Serum free medium 
SH2   Src homology domain 2 
SHP-2   Src homology protein 2 tyrosine phosphatase-2 
SIEM-Luc   sis-inducible element; STAT3 reporter with firefly luciferase 
sIL-6R   soluble IL-6R  
SOCS3   Suppressor of cytokine signaling 3 
SSC   Saline-sodium citrate 
STAT3   Signal transducer and activator of transcription 3 
T 
TEMED   Tetramethylethylenediamine 
Tet   Tetracycline 
TetR   Tet repressor protein 
TK-RL   Thymidin-Kinase-Renilla-Luciferase 
TRE   Tetracycline responsive element 
Tris   tris(hydroxymethyl)aminomethane 
tTA   Tetracycline transactivator protein 
rtTA   Reverse tetracycline transactivator protein 
Tyr   Tyrosine 
U 
U   Unit(s) 
UV   Ultraviolet  
V 
V   Volt  
Val   Valine 
v/v   Volume per Volume  
vIL-6   Viral interleukin-6  
VP16   Herpes simplex virus protein 
W 
w/v   Weight per Volume  
WT   Wildtype 
WB   Western blot 
w/o   without 
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Y 
YFP   Yellow fluorescent protein 
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